<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Stem cell therapy for dilated cardiomyopathy - Diaz-Navarro, R - 2021 | Cochrane Library</title> <meta content="Stem cell therapy for dilated cardiomyopathy - Diaz-Navarro, R - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013433.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Stem cell therapy for dilated cardiomyopathy - Diaz-Navarro, R - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013433.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013433.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Stem cell therapy for dilated cardiomyopathy" name="citation_title"/> <meta content="Rienzi Diaz-Navarro" name="citation_author"/> <meta content="Universidad de Valparaiso" name="citation_author_institution"/> <meta content="diaz.rienzi@gmail.com" name="citation_author_email"/> <meta content="Gerard Urrútia" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP)" name="citation_author_institution"/> <meta content="John GF Cleland" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Daniel Poloni" name="citation_author"/> <meta content="Universidad de Valparaiso" name="citation_author_institution"/> <meta content="Francisco Villagran" name="citation_author"/> <meta content="Universidad de Valparaiso" name="citation_author_institution"/> <meta content="Roberto Acosta-Dighero" name="citation_author"/> <meta content="Shrikant I Bangdiwala" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Gabriel Rada" name="citation_author"/> <meta content="Pontificia Universidad Católica de Chile" name="citation_author_institution"/> <meta content="Eva Madrid" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD013433.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/07/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013433.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013433.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013433.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Arrhythmias, Cardiac [epidemiology]; Bias; Cardiomyopathy, Dilated [mortality, *therapy]; Cause of Death; Granulocyte Colony-Stimulating Factor [therapeutic use]; Placebos [therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; *Stem Cell Transplantation [adverse effects, mortality]; Walk Test; Watchful Waiting" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013433.pub2&amp;doi=10.1002/14651858.CD013433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ytRBD0EW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013433\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013433\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013433.pub2",title:"Stem cell therapy for dilated cardiomyopathy",firstPublishedDate:"Jul 21, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013433.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013433.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013433.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013433.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013433.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013433.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013433.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013433.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013433.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013433.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2588 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013433.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-sec-0109"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-sec-0103"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/appendices#CD013433-sec-0114"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/table_n/CD013433StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/table_n/CD013433StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Stem cell therapy for dilated cardiomyopathy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information#CD013433-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Rienzi Diaz-Navarro</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information#CD013433-cr-0005">Gerard Urrútia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information#CD013433-cr-0006">John GF Cleland</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information#CD013433-cr-0007">Daniel Poloni</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information#CD013433-cr-0008">Francisco Villagran</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information#CD013433-cr-0009">Roberto Acosta-Dighero</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information#CD013433-cr-0010">Shrikant I Bangdiwala</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information#CD013433-cr-0011">Gabriel Rada</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information#CD013433-cr-0012">Eva Madrid</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information/en#CD013433-sec-0118">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 July 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013433.pub2">https://doi.org/10.1002/14651858.CD013433.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013433-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013433-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013433-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013433-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013433-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013433-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013433-abs-0001" lang="en"> <section id="CD013433-sec-0001"> <h3 class="title" id="CD013433-sec-0001">Background</h3> <p>Stem cell therapy (SCT) has been proposed as an alternative treatment for dilated cardiomyopathy (DCM), nonetheless its effectiveness remains debatable. </p> </section> <section id="CD013433-sec-0002"> <h3 class="title" id="CD013433-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of SCT in adults with non‐ischaemic DCM.</p> </section> <section id="CD013433-sec-0003"> <h3 class="title" id="CD013433-sec-0003">Search methods</h3> <p>We searched CENTRAL in the Cochrane Library, MEDLINE, and Embase for relevant trials in November 2020. We also searched two clinical trials registers in May 2020. </p> </section> <section id="CD013433-sec-0004"> <h3 class="title" id="CD013433-sec-0004">Selection criteria</h3> <p>Eligible studies were randomized controlled trials (RCT) comparing stem/progenitor cells with no cells in adults with non‐ischaemic DCM. We included co‐interventions such as the administration of stem cell mobilizing agents. Studies were classified and analysed into three categories according to the comparison intervention, which consisted of no intervention/placebo, cell mobilization with cytokines, or a different mode of SCT. </p> <p>The first two comparisons (no cells in the control group) served to assess the efficacy of SCT while the third (different mode of SCT) served to complement the review with information about safety and other information of potential utility for a better understanding of the effects of SCT. </p> </section> <section id="CD013433-sec-0005"> <h3 class="title" id="CD013433-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened all references for eligibility, assessed trial quality, and extracted data. We undertook a quantitative evaluation of data using random‐effects meta‐analyses. We evaluated heterogeneity using the I² statistic. We could not explore potential effect modifiers through subgroup analyses as they were deemed uninformative due to the scarce number of trials available. We assessed the certainty of the evidence using the GRADE approach. We created summary of findings tables using GRADEpro GDT. We focused our summary of findings on all‐cause mortality, safety, health‐related quality of life (HRQoL), performance status, and major adverse cardiovascular events. </p> </section> <section id="CD013433-sec-0006"> <h3 class="title" id="CD013433-sec-0006">Main results</h3> <p>We included 13 RCTs involving 762 participants (452 cell therapy and 310 controls). Only one study was at low risk of bias in all domains. There were many shortcomings in the publications that did not allow a precise assessment of the risk of bias in many domains. Due to the nature of the intervention, the main source of potential bias was lack of blinding of participants (performance bias). Frequently, the format of the continuous data available was not ideal for use in the meta‐analysis and forced us to seek strategies for transforming data in a usable format. </p> <p>We are uncertain whether SCT reduces all‐cause mortality in people with DCM compared to no intervention/placebo (mean follow‐up 12 months) (risk ratio (RR) 0.84, 95% confidence interval (CI) 0.54 to 1.31; I² = 0%; studies = 7, participants = 361; very low‐certainty evidence). We are uncertain whether SCT increases the risk of procedural complications associated with cells injection in people with DCM (data could not be pooled; studies = 7; participants = 361; very low‐certainty evidence). We are uncertain whether SCT improves HRQoL (standardized mean difference (SMD) 0.62, 95% CI 0.01 to 1.23; I² = 72%; studies = 5, participants = 272; very low‐certainty evidence) and functional capacity (6‐minute walk test) (mean difference (MD) 70.12 m, 95% CI –5.28 to 145.51; I² = 87%; studies = 5, participants = 230; very low‐certainty evidence). SCT may result in a slight functional class (New York Heart Association) improvement (data could not be pooled; studies = 6, participants = 398; low‐certainty evidence). None of the included studies reported major adverse cardiovascular events as defined in our protocol. SCT may not increase the risk of ventricular arrhythmia (data could not be pooled; studies = 8, participants = 504; low‐certainty evidence). </p> <p>When comparing SCT to cell mobilization with granulocyte‐colony stimulating factor (G‐CSF), we are uncertain whether SCT reduces all‐cause mortality (RR 0.46, 95% CI 0.16 to 1.31; I² = 39%; studies = 3, participants = 195; very low‐certainty evidence). We are uncertain whether SCT increases the risk of procedural complications associated with cells injection (studies = 1, participants = 60; very low‐certainty evidence). SCT may not improve HRQoL (MD 4.61 points, 95% CI –5.62 to 14.83; studies = 1, participants = 22; low‐certainty evidence). SCT may improve functional capacity (6‐minute walk test) (MD 140.14 m, 95% CI 119.51 to 160.77; I² = 0%; studies = 2, participants = 155; low‐certainty evidence). None of the included studies reported MACE as defined in our protocol or ventricular arrhythmia. </p> <p>The most commonly reported outcomes across studies were based on physiological measures of cardiac function where there were some beneficial effects suggesting potential benefits of SCT in people with non‐ischaemic DCM. However, it is unclear if this intermediate effects translates into clinical benefits for these patients. </p> <p>With regard to specific aspects related to the modality of cell therapy and its delivery, uncertainties remain as subgroup analyses could not be performed as planned, making it necessary to wait for the publication of several studies that are currently in progress before any firm conclusion can be reached. </p> </section> <section id="CD013433-sec-0007"> <h3 class="title" id="CD013433-sec-0007">Authors' conclusions</h3> <p>We are uncertain whether SCT in people with DCM reduces the risk of all‐cause mortality and procedural complications, improves HRQoL, and performance status (exercise capacity). SCT may improve functional class (NYHA), compared to usual care (no cells). </p> <p>Similarly, when compared to G‐CSF, we are also uncertain whether SCT in people with DCM reduces the risk of all‐cause mortality although some studies within this comparison observed a favourable effect that should be interpreted with caution. SCT may not improve HRQoL but may improve to some extent performance status (exercise capacity). Very low‐quality evidence reflects uncertainty regarding procedural complications. These suggested beneficial effects of SCT, although uncertain due to the very low certainty of the evidence, are accompanied by favourable effects on some physiological measures of cardiac function. </p> <p>Presently, the most effective mode of administration of SCT and the population that could benefit the most is unclear. Therefore, it seems reasonable that use of SCT in people with DCM is limited to clinical research settings. Results of ongoing studies are likely to modify these conclusions. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013433-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013433-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013433-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013433-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013433-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013433-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013433-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013433-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013433-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013433-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013433-abs-0002" lang="en"> <h3>Bone marrow cells in non‐ischaemic dilated cardiomyopathy</h3> <p><b>Review question</b> </p> <p>Are bone marrow cells safe and effective as a treatment for non‐ischaemic dilated cardiomyopathy (DCM)? </p> <p><b>Background</b> </p> <p>DCM is a disorder of the heart muscle with heart dilation (heart muscle becomes stretched) and impaired contraction, in the absence of high blood pressure, damaged or diseased heart valves, or heart disease present at birth or related to myocardial infarction (heart attack). The current standard of treatment is based on medicines and cardiac devices. However, DCM is still one of the leading causes of heart transplantation in adults. </p> <p>Stem cells are special cells produced in the bone marrow that are able to develop into many different cell types. Giving stem cells directly into the heart muscle has been proposed as an alternative treatment to reduce or stop further deterioration in heart function in people with DCM. </p> <p><b>Study characteristics</b> </p> <p>We selected randomized controlled trials (RCTs; clinical studies where people are randomly put into one of two or more treatment groups) comparing the infusion of bone marrow‐derived stem cells into the heart muscle with the usual‐care (control) treatment in people diagnosed with DCM. We searched multiple databases for trials up to 10 November 2020. </p> <p>We included 13 RCTs involving 762 participants (452 receiving stem cell therapy and 310 controls). The trials included people with severe symptoms of ischaemic (following a heart attack) and non‐ischaemic DCM. We selected only the data from non‐ischaemic DCM. </p> <p>The studies included an average of 60 people aged about 45 to 58.5 years and 50% to 89% men in each trial. Following therapy, the participants were assessed for six months to five years, with most at one year. One study declared a private funding whereas seven others had public or governmental funding, two had non‐profit funding, and four did not report this information. </p> <p><b>Key results</b> </p> <p>SCT versus control: very low‐quality evidence reflects uncertainty regarding mortality, procedural complications, health‐related quality of life and exercise capacity. Low‐quality evidence suggests that SCT may slightly improve deterioration of heart function and may not increase the risk of abnormal heartbeats in people with DCM. No studies reported other relevant outcomes such as major cardiac adverse events. </p> <p>STC plus cytokine versus control: very low‐quality evidence reflects uncertainty regarding mortality. Low‐quality evidence suggests that SCT plus cytokine may not improve health‐related quality of life but may improve exercise capacity as well as some physiological measures related to cardiac function (although it is unclear to what extent these latter outcomes are associated with relevant clinical benefits for patients). Hence, the results should be interpreted with caution. Very low‐quality evidence reflects uncertainty regarding procedural complications. No studies reported major cardiac adverse events or abnormal heartbeats. </p> <p>Due to the limited number of studies we could not perform analyses to identify which specific features of SCT and clinical characteristics of patients are associated with better results. Thus, more research is needed to establish the role of SCT in the treatment of DCM and the most effective therapies. </p> <p><b>Quality of evidence</b> </p> <p>The evidence in this review is of low to very low quality due to the small number of events, results not similar across studies, risk of bias, and issues with study design. Furthermore, the limitations in the reporting of most studies made it difficult to obtain and use the information to reach clearer conclusions. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013433-sec-0109" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013433-sec-0109"></div> <h3 class="title" id="CD013433-sec-0110">Implications for practice</h3> <section id="CD013433-sec-0110"> <p>This systematic review and meta‐analysis found that stem cell transplantation (SCT) appears to have little favourable effects in the treatment of people with dilated cardiomyopathy (DCM), while very low‐quality evidence reflects uncertainty regarding procedural complications. It is possible that some benefits might be obtained if SCT is administered in combination with peripheral administration of granulocyte‐colony stimulating factor (G‐CSF), but more robust information and data are needed to draw a clear conclusion. Specific aspects related to the modality of cell therapy or its delivery (type and origin of cells, dose, route of administration, number of infusions, etc.), or both, remain uncertain. There are several ongoing trials that could provide new evidence and modify our conclusions. </p> </section> <h3 class="title" id="CD013433-sec-0111">Implications for research</h3> <section id="CD013433-sec-0111"> <p>Most studies included in this review administered bone marrow‐derived mononuclear cells. The lack of a clear benefit of SCT observed in this review may be explained by the use of adult stem cells delivered in their native state, as these cells have a limited capacity for differentiation. Future randomized trials using stem cells should take into account guiding criteria to identify the best candidates for this therapy (<a href="./references#CD013433-bbs2-0044" title="BlauHM , DaleyGQ . Stem cells in the treatment of disease. New England Journal of Medicine2019;380(18):1748-60.">Blau 2019</a>; <a href="./references#CD013433-bbs2-0046" title="ChienKR , FrisénJ , Fritsche-DanielsonR , MeltonDA , MurryCE , WeissmanIL . Regenerating the field of cardiovascular cell therapy. Nature Biotechnology2019;37(3):232-7.">Chien 2019</a>; <a href="./references#CD013433-bbs2-0078" title="MenaschéP . Cell therapy trials for heart regeneration-lessons learned and future directions. Nature Reviews. Cardiology2018;15(11):659-71.">Menasché 2018</a>), including identification of the best responders, choosing the proper cell phenotype, the best dose of and delivery route for the cells, and considering repetitive dosing. </p> <p>A different stem cell phenotype, cardiopoietic cells, has been demonstrated to be safe and effective in people with ischaemic cardiomyopathy, and this approach represents a rationale to be considered for use in a broader spectrum of cardiovascular disorders including DCM (<a href="./references#CD013433-bbs2-0095" title="TerzicA , BehfarA . CardioPulse: regenerative medicine in the practice of cardiology. European Heart Journal2016;37(14):1089-90.">Terzic 2016</a>). </p> <p>The benefit of SCT appears to depend on left ventricular dilation, so people with an initial left ventricular end‐diastolic volume of 200 mL to 370 mL have a greater probability of a better response to SCT, while those with less than 200 mL or greater than 370 mL do not seem to respond to SCT (<a href="./references#CD013433-bbs2-0039" title="BartunekJ , TerzicA , DavisonBA , FilippatosGS , RadovanovicS , BeleslinB , et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. European Heart Journal2017;38(9):648-60.">Bartunek 2017</a>). Therefore, the selection of patients for SCT should include people with an LVEDV of 200 mL to 370 mL, which may be considered a predictor of beneficial cardiopoietic SCT response (<a href="./references#CD013433-bbs2-0040" title="BartunekJ , TerzicA , BehfarA , WijnsW . Clinical experience with regenerative therapy in heart failure: advancing care with cardiopoietic stem cell interventions. Circulation Research2018;122(10):1344-6.">Bartunek 2018</a>). This benefit has also been demonstrated experimentally (<a href="./references#CD013433-bbs2-0103" title="YamadaS , ArrellDK , RosenowCS , BartunekJ , BehfarA , TerzicA . Ventricular remodeling in ischemic heart failure stratifies responders to stem cell therapy. Stem Cells Translational Medicine2020;9(1):74-9.">Yamada 2020</a>). Hence, a baseline enlargement of the left ventricle of 200 mL to 370 mL is a key factor that may influence the therapeutic responsiveness to SCT. </p> <p>Establishing an evidence‐based posology paradigm is also required to ensure accurate titration of regenerative therapies and advance the science of regenerative medicine (<a href="./references#CD013433-bbs2-0096" title="TerzicA , BehfarA . Posology for regenerative therapy. Circulation Research2017;121(11):1213-5.">Terzic 2017</a>). </p> <p>The use of repeat dosing of bone marrow‐derived stem cells three to six months after the initial intracoronary infusion of cells has been associated with improved clinical outcomes compared with a single treatment at two years of follow‐up (<a href="./references#CD013433-bbs2-0036" title="AssmusB , AlakmehS , De RosaS , BönigH , HermannE , LevyWC , et al. Improved outcome with repeated intracoronary injection of bone marrow-derived cells within a registry: rationale for the randomized outcome trial REPEAT. European Heart Journal2016;37(21):1659-66.">Assmus 2016</a>). Repetitive cell dosing suggests pharmacodynamic synergism to rescue regenerative cell reserve and represents an emerging paradigm in regenerative medicine (<a href="./references#CD013433-bbs2-0042" title="BehfarA , GershB , TerzicA . Repetition rescues regenerative reserve. European Heart Journal2016;37(21):1667-70.">Behfar 2016</a>). </p> <p>Beyond cell quantity per se, the delivery method is another factor that may influence the effectiveness of SCT. Intracoronary cell injections require cells to migrate into the myocardium, which may result in lower engraftment rates than intramyocardial injections (<a href="./references#CD013433-bbs2-0096" title="TerzicA , BehfarA . Posology for regenerative therapy. Circulation Research2017;121(11):1213-5.">Terzic 2017</a>). Transendocardial administration appears to be a better approach than intracoronary delivery, as injections can be targeted using electromechanical mapping to identify areas of viable and dysfunctional myocardium (<a href="./references#CD013433-bbs2-0037" title="BartunekJ , BehfarA , DolatabadiD , VanderheydenM , OstojicM , DensJ , et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. Journal of the American College of Cardiology2013;61(23):2329-38.">Bartunek 2013</a>). Moreover, novel catheters with incremental side holes for the transendocardial administration of stem cells can be used, because they enhance myocardial stem cell retention and improve delivery (<a href="./references#CD013433-bbs2-0038" title="BartunekJ , DavisonB , ShermanW , PovsicT , HenryTD , GershB , et al. Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. European Journal of Heart Failure2016;18(2):160-8.">Bartunek 2016</a>). </p> <p>In summary, new studies are needed to explore the effects of specific modalities of SCT in well‐selected specific subgroups of people with DCM who have a greater probability of obtaining a clinically relevant benefit. These studies must have a rigorous design, be transparent, with long‐term follow‐up, be focused on measuring effects on clinically relevant variables, have clear definitions of events, and provide a complete report according to the CONSORT guidelines. Until then, this intervention should remain within the scope of clinical research. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013433-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013433-sec-0008"></div> <div class="table" id="CD013433-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Stem cell therapy compared to control for dilated cardiomyopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>SCT compared to control for DCM</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> DCM (non‐ischaemic)<br/><b>Setting:</b> hospital for procedure; follow‐up ambulatory<br/><b>Intervention:</b> SCT (any type)<br/><b>Comparison:</b> Control (no intervention or sham intervention) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with SCT</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Mean follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>361<br/>(7 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b><br/>(0.54 to 1.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>165 per 1000</b> </p> <p>(106 to 257)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether SCT reduces all‐cause mortality in people with DCM.</p> <p>We excluded 1 further study (29 participants) from the meta‐analysis because there were no events in either group (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>). </p> <p>See <a href="./full#CD013433-tbl-0002">Table 1</a> for more details on mortality. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Procedural complications</b> </p> <p>Within 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>361</p> <p>(7 studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether SCT increases the risk of procedural complications in people with DCM. </p> <p>The definition of this outcome varied widely between studies. In some, it was included as an adverse event. For this reason, this outcome is only presented narratively. Overall, SCT is perceived as a safe intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Mean follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>272<br/>(5 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>d,e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD 0.62 higher</b> </p> <p>(0.01 higher to 1.23 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether SCT improves health‐related quality of life in people with DCM. </p> <p>It was not possible to calculate mean value in the control group, considering that studies used different scales. Using <a href="./references#CD013433-bbs2-0048" title="CohenJ . Statistical Power Analysis in the Behavioural Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc, 1988.">Cohen 1988</a>'s approach, we interpret this SMD as a medium‐to‐large effect estimate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Performance status – 6MWT (m)</b> </p> <p>Mean follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230<br/>(5 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b> </p> <p><sup>a,b,e,</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246.9 (SD 141.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 70.12 m higher</b> </p> <p>(5.28 lower to 145.51 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether SCT improves performance status assessed by 6MWT in people with DCM. </p> <p>For the risk with control we used the mean average of the control groups of the included studies. </p> <p>1 additional study assessed exercise time and found an improvement with SCT (P = 0.01) but a decrease in the control group after 1 year (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Performance status – change in functional class (NYHA)</b> </p> <p>Mean follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>398</p> <p>(6 studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SCT may result in a slight functional class (NYHA) improvement in people with DCM.</p> <p>6 studies reported change in functional class (NYHA) in a diverse way that did not allow pooling of data. All studies reported a significant improvement with SCT. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MACE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies reported MACE as defined in our protocol (<a href="./references#CD013433-bbs2-0105" title="Diaz-NavarroR , UrrútiaG , ClelandJG , PoloniD , VillagranF , BangdiwalaS , et al. Stem cell therapy for dilated cardiomyopathy. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD013433. [DOI: 10.1002/14651858.CD013433]">Diaz‐Navarro 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular arrhythmia</b> </p> <p>Mean follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>504</p> <p>(8 studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SCT may not increase the risk of ventricular arrhythmia in people with DCM.</p> <p>Overall, ventricular arrhythmia rates were similar between groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>6MWT:</b> 6‐minute walk test; <b>CI:</b> confidence interval; <b>DCM:</b> dilated cardiomyopathy; <b>MACE:</b> major adverse cardiovascular events; <b>MD:</b> mean difference; <b>NYHA:</b> New York Heart Association; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SCT:</b> stem cell therapy; <b>SD:</b> standard deviation; <b>SMD:</b> standardized mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to unclear risk of bias related to randomization and allocation concealment and high risk of attrition bias and selective reporting.<br/><sup>b</sup>Downgraded two levels for imprecision due to optimal information size not being met and confidence intervals including the threshold of null effect.<br/><sup>c</sup>Downgraded two levels for inconsistency as the outcome had high heterogeneity within included studies.<br/><sup>d</sup>Downgraded one level due to unclear risk of bias related to randomization and allocation, and high risk of bias regarding blinding.<br/><sup>e</sup>Downgraded two levels due to inconsistency (I² = 80%). The substantial heterogeneity observed was attributable to <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>, a robust trial with a relatively large sample size, which did not show a beneficial effect of SCT on this outcome (measured using the Minnesota Living with Heart Failure Questionnaire), contrary to what is suggested by the other studies.<br/><sup>f</sup>Downgraded one level for imprecision due to wide confidence intervals (reflecting both a null and a relevant effect).<br/><sup>g</sup>Downgraded one level for indirectness due to different definitions of the outcome. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013433-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">1.</span> <span class="table-title">Summary of mortality rates</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study (arm)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Follow‐up</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>SCT</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>No SCT</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a><b> </b>(autologous) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a><b> </b>(allogeneic) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 12 m (3 yr)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 12 m (5 yr)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a> (IC) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a> (TE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a> (repetitive) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a><b> </b>(single) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 12  m (18 m)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Up to 12 m</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&gt; 12 m</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35/113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TOTAL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48/432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59/256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.0%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>IC: intracoronary; m: month; SCT: stem cell therapy; TE: transendocardial; yr: year.</p> <p><sup>a</sup><a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a> studied mixed population. Data shown here correspond specifically to participants with non‐ischaemic dilated cardiomyopathy. </p> <p><sup>b</sup><a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a> assessed mortality at 6 months, but provides information on additional deaths observed up to 12 months only in the SCT group. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013433-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Stem cell therapy (any type) compared to peripheral therapy with granulocyte colony‐stimulating factor for dilated cardiomyopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>SCT (any type) compared to G‐CSF for DCM</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> DCM (non‐ischaemic)<br/><b>Setting:</b> hospital for procedure, follow‐up ambulatory<br/><b>Intervention:</b> SCT (any type)<br/><b>Comparison:</b> G‐CSF (peripheral therapy with granulocyte colony‐stimulating factor) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with SCT</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up to 5 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195<br/>(3 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.46</b><br/>(0.16 to 1.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>128 per 1000</b> </p> <p>(45 to 365)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether SCT reduces all‐cause mortality in people with DCM.</p> <p>See <a href="./full#CD013433-tbl-0002">Table 1</a> for more details on mortality. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Procedural complications (safety)</b> </p> <p>Follow‐up 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60</p> <p>(1 study)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether SCT increases the risk of procedural complications in people with DCM. </p> <p><a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> assessed the safety of the SCT infusion by measurement of creatine kinase and troponin T concentrations 12 hours after infusion. There were no cases of distal coronary artery occlusion, acute cardiac dysfunction, or significant creatine kinase or troponin T release. 1 participant experienced a localized coronary dissection during infusion. No complications or adverse events associated with G‐CSF therapy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Follow‐up 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22<br/>(1 study) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.39</p> <p>(SD 14.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 4.61 higher</b> (5.62 lower to 14.83 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCT may not improve health‐related quality of life in people with DCM.</p> <p>For the risk with control, we used the mean of the control group of the only included study. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Performance status – functional class (NYHA)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Performance status – exercise tolerance (6MWT) (m)</b> </p> <p>Follow‐up to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155<br/>(2 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138.9</p> <p>(SD 61.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 140.14 m higher</b> (119.51 higher to 160.77 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCT may improve performance status assessed by 6MWT in people with DCM.</p> <p>For the 2 studies included in this analysis, we obtained raw data from a figure by using a software. </p> <p>For the risk with control, we used the mean average of the control groups of the included studies. </p> <p>1 additional study assessed exercise time and found an improvement with SCT (P = 0.01) but a decrease in the control group after 1 year (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MACE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported MACE as defined in our protocol (<a href="./references#CD013433-bbs2-0105" title="Diaz-NavarroR , UrrútiaG , ClelandJG , PoloniD , VillagranF , BangdiwalaS , et al. Stem cell therapy for dilated cardiomyopathy. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD013433. [DOI: 10.1002/14651858.CD013433]">Diaz‐Navarro 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>6MWT:</b> 6‐minute walk test; <b>CI:</b> confidence interval; <b>DCM:</b> dilated cardiomyopathy; <b>G‐CSF:</b> granulocyte colony‐stimulating factor; <b>MD:</b> mean difference; <b>NYHA:</b> New York Heart Association; <b>RR:</b> risk ratio; <b>SCT:</b> stem cell therapy; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for risk of bias due to serious concerns about selective reporting with two studies. In <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>, there were inconsistencies between the trial register (NCT00629018) and the final publication regarding the total number of participants (110 vs 55), the time point for the outcomes (5 years vs 1 year) and some of the outcomes that were planned and finally reported, and there is a high suspicion that participants reported in <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a> were also included in the <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a> analysis. For <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>, the trial was registered as a phase II study to compare between intracoronary versus intramyocardial injection of SCT (NCT01350310), nevertheless the publication described a comparison between SCT and no cell therapy. We made several attempts to contact the authors with no reply.<br/><sup>b</sup>Downgraded one level for indirectness due to concerns about the population. <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a> has a ClinicalTrials.gov record (NCT01350310), which had an actual primary completion date of August 2014, but the study was published in 2013 after 5 years' follow‐up. We made many attempts to contact the author with no reply.<br/><sup>c</sup>Downgraded two levels for imprecision due to optimal information size not being met. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013433-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013433-sec-0009"></div> <section id="CD013433-sec-0010"> <h3 class="title" id="CD013433-sec-0010">Description of the condition</h3> <p>Dilated cardiomyopathy (DCM), also known as non‐ischaemic DCM, is a heart muscle disorder defined by the presence of left ventricular or biventricular systolic dysfunction and dilation in the absence of hypertension, valvular, congenital, or ischaemic heart disease (<a href="./references#CD013433-bbs2-0045" title="BozkurtB , ColvinM , CookJ , CooperJT , DeswalA , FonarowGC , et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation2016;134:e579-646.">Bozkurt 2016</a>; <a href="./references#CD013433-bbs2-0083" title="PintoYM , ElliotPM , ArbustiniE , AdlerY , AnastasakisA , BöhmM , et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal2016;37(23):1850-8.">Pinto 2016</a>). DCM is the most common form of non‐ischaemic cardiomyopathy worldwide (<a href="./references#CD013433-bbs2-0070" title="JefferiesJL , TowbinJA . Dilated cardiomyopathy. Lancet2010;375(9716):752-62.">Jefferies 2010</a>; <a href="./references#CD013433-bbs2-0076" title="McKennaWJ , MaronBJ , ThieneG . Classification, epidemiology, and global burden of cardiomyopathies. Circulation Research2017;121:722-30.">McKenna 2017</a>), and represents one of the leading causes for heart transplantation in adults (<a href="./references#CD013433-bbs2-0081" title="MerloM , CannatáA , VitaglianoA , ZambonE , LardieriG , SinagraG . Clinical management of dilated cardiomyopathy: current knowledge and future perspectives. Expert Review of Cardiovascular Therapy2016;14(2):137-40.">Merlo 2016</a>; <a href="./references#CD013433-bbs2-0093" title="StehlikJ , EdwardsLB , KucheryavayaAY , BendenC , ChristieJD , DobbelsF , et al. The registry of the International Society of Heart and Lung Transplantation: twenty-eight adult heart transplantation report. Journal of Heart and Lung Transplantation2011;30(10):1078-94.">Stehlik 2011</a>). DCM was first described by the World Health Organization (WHO) in 1980 (<a href="./references#CD013433-bbs2-0102" title="World Health Organization/International Society and Federation of Cardiology. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. British Heart Journal1980;44(6):672-3.">WHO/ISFC 1980</a>), and its prevalence is estimated at 1 in 2500 people (<a href="./references#CD013433-bbs2-0067" title="HershbergerRE , HedgesDJ , MoralesA . Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nature Reviews. Cardiology2013;10(9):531-47.">Hershberger 2013</a>). Most people with DCM present with symptoms of heart failure, including dyspnoea and fatigue on exertion, orthopnoea, ankle oedema, and excessive sweating (<a href="./references#CD013433-bbs2-0050" title="DecGW , FusterV . Idiopathic dilated cardiomyopathy. New England Journal of Medicine1994;331:1564-75.">Dec 1994</a>; <a href="./references#CD013433-bbs2-0100" title="WeintraubRG , SemsarianC , MacdonaldP . Dilated cardiomyopathy. Lancet2017;390(10092):400-41.">Weintraub 2017</a>). Survival in people with DCM is extremely poor after the diagnosis, and early studies have shown that most deaths occur within the first two years of follow‐up (<a href="./references#CD013433-bbs2-0053" title="DíazRA , ObasohanA , OakleyCM . Prediction of outcome in dilated cardiomyopathy. British Heart Journal1987;58(4):393-9.">Díaz 1987</a>; <a href="./references#CD013433-bbs2-0061" title="FusterV , GershBJ , TajikAJ , BrandenburgRO , FryeRL . The natural history of idiopathic dilated cardiomyopathy. American Journal of Cardiology1981;47(3):525-31.">Fuster 1981</a>). Optimal medical therapy as a first‐line treatment, either with or without device therapy (<a href="./references#CD013433-bbs2-0085" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37:2129-200.">Ponikowski 2016</a>; <a href="./references#CD013433-bbs2-0104" title="YancyC , JessupM , BozkurtB , ButlerJ , CaseyD , DraznerM , et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2013;128(16):e240-27.">Yancy 2013</a>), has progressively and significantly improved the long‐term prognosis of DCM since the early 1990s (<a href="./references#CD013433-bbs2-0079" title="MerloM , PivettaA , PinamontiB , StolfoD , ZecchinM , BarbatiG , et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. European Journal of Heart Failure2014;16(3):317-24.">Merlo 2014</a>). However, although a proportion of patients recover cardiac function, in the long term there is a trend towards worsening of left ventricular function (<a href="./references#CD013433-bbs2-0080" title="MerloM , StolfoD , AnziniM , NegriF , PinamontiB , BarbatiG , et al. Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist?Journal of the American Heart Association2015;4(1):e001504.">Merlo 2015</a>). Cardiac transplantation is reserved for extremely ill patients and for those needing continuous intravenous inotrope support, mechanical ventilatory support or ventricular assist device support (<a href="./references#CD013433-bbs2-0070" title="JefferiesJL , TowbinJA . Dilated cardiomyopathy. Lancet2010;375(9716):752-62.">Jefferies 2010</a>). The use of stem cell therapy (SCT) may be an alternative treatment to reduce or stop further deterioration of left ventricular function in people with end‐stage DCM. However, two systematic reviews have shown some benefits in terms of systolic function and mortality but not in exercise tolerance (<a href="./references#CD013433-bbs2-0074" title="LuY , WangY , LinM , ZhouJ , WangZ , JiangM , et al. A systematic review of randomised controlled trials examining the therapeutic effects of adult bone marrow-derived stem cells for non-ischaemic dilated cardiomyopathy. Stem Cell Research &amp; Therapy2016;7(1):186.">Lu 2016</a>; <a href="./references#CD013433-bbs2-0075" title="Marquis-GravelG , StevensLM , ManosurS , AvramR , NoiseuxN . Stem cell therapy for the treatment of nonischemic cardiomyopathy: a systematic review of the literature and meta-analysis of randomized controlled trials. Canadian Journal of Cardiology2014;30(11):1378-84.">Marquis‐Gravel 2014</a>). </p> </section> <section id="CD013433-sec-0011"> <h3 class="title" id="CD013433-sec-0011">Description of the intervention</h3> <p>Stem cells are types of cells with special characteristics, such as proliferation, self‐renewal, regeneration, and the possibility of generating different lineages of differentiated progeny (<a href="./references#CD013433-bbs2-0043" title="BlauHM , BrazeltonTR , WeimannJM . The evolving concept of a stem cell: entity or function?Cell2001;105(7):829-41.">Blau 2001</a>). These features have prompted the development of SCT. The objective of SCT in the treatment of DCM is to achieve cardiac muscle regeneration and recovery of functional capacity, either by replacing the dead myocardium or by activating physiological repair mechanisms (<a href="./references#CD013433-bbs2-0078" title="MenaschéP . Cell therapy trials for heart regeneration-lessons learned and future directions. Nature Reviews. Cardiology2018;15(11):659-71.">Menasché 2018</a>). The first description of cell transplantation into the human myocardium was a case report published in 2001 using skeletal myoblasts (<a href="./references#CD013433-bbs2-0077" title="MenaschéP , HagegeAA , ScorsinM , PouzetB , DesnosM , DubocD , et al. Myoblast transplantation for heart failure. Lancet2001;357(9252):279-80.">Menasché 2001</a>). Since then, cell‐based therapies have been used in different trials for treating ischaemic and non‐ischaemic heart failure (<a href="./references#CD013433-bbs2-0058" title="FisherSA , DoreeC , MathurA , TaggartDP , Martin-RendonE . Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database of Systematic Reviews2016, Issue 12. Art. No: CD007888. [DOI: 10.1002/14651858.CD007888.pub3]">Fisher 2016a</a>; <a href="./references#CD013433-bbs2-0078" title="MenaschéP . Cell therapy trials for heart regeneration-lessons learned and future directions. Nature Reviews. Cardiology2018;15(11):659-71.">Menasché 2018</a>; <a href="./references#CD013433-bbs2-0084" title="PoglajenG , ZemljičG , FrljakS , CerarA , AndročecV , SeverM , et al. Stem cell therapy in patients with chronic nonischemic heart failure. Stem Cells International2018;2018:6487812.">Poglagen 2018</a>; <a href="./references#CD013433-bbs2-0098" title="VrtovecB . Cell therapy for nonischemic cardiomyopathy: current status and future perspectives. Circulation Research2018;5(122):28-30.">Vrtovec 2018a</a>). </p> <p>To date, several stem cell types, autologous and allogeneic, have been considered for the treatment of people with chronic heart failure secondary to ischaemic cardiomyopathy and DCM. These include skeletal myoblasts, haematopoietic stem cells, mesenchymal stem cells, cardiac stem cells, and cardiosphere‐derived cells (<a href="./references#CD013433-bbs2-0078" title="MenaschéP . Cell therapy trials for heart regeneration-lessons learned and future directions. Nature Reviews. Cardiology2018;15(11):659-71.">Menasché 2018</a>). Haematopoietic stem cells may be collected from peripheral venous blood after a mobilization procedure involving injection of a growth‐stimulating factor (usually granulocyte colony‐stimulating factor, G‐CSF) over the previous days to increase the number of progenitor cells in the blood and to later culture these cells ex vivo. Bone marrow‐derived stem cells may also be isolated directly from bone marrow aspiration, a procedure in which a small sample of liquid bone is aspirated with a syringe under local anaesthesia, usually from the ilium of people receiving cell therapy (<a href="./references#CD013433-bbs2-0094" title="StrauerBE , BrehmM , ZeusT , KösteringM , HernadezA , SorgRV , et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation2002;106:1913-8.">Strauer 2002</a>). Afterwards, bone marrow mononuclear cells (BMMC) are separated from other bone marrow cells (BMC) by density gradient centrifugation (<a href="./references#CD013433-bbs2-0035" title="AssmusB , SchachingerV , TeupeC , BrittenM , LehmannR , DobertN , et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation2002;106(24):3009-17.">Assmus 2002</a>; <a href="./references#CD013433-bbs2-0056" title="ErbsS , LinkeA , AdamsV , LenkK , ThieleH , DiederichKW , et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circulation Research2005;97(8):756-62.">Erbs 2005</a>). Stem cells are then administered to the patient using different delivery methods. The cells can be delivered through coronary arteries (<a href="./references#CD013433-bbs2-0047" title="ChoudryF , HamshereS , SaundersN , VeerapenJ , BavnbekK , KnightC , et al. A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trial. European Heart Journal2016;37(3):256-63.">Choudry 2016</a>), coronary sinus (<a href="./references#CD013433-bbs2-0082" title="PatelAN , MittalS , TuranG , WintersAA , HenryTD , InceH , et al. REVIVE trial: retrograde delivery of autologous bone marrow in patients with heart failure. Stem Cells Translational Medicine2015;4(9):1021-7.">Patel 2015</a>), or peripheral veins (<a href="./references#CD013433-bbs2-0065" title="HareJM , TraverseJH , HenryTD , DibN , StrumpfRK , SchulmanSP , et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology2009;54(24):2277-86.">Hare 2009</a>). Alternatively, direct intramyocardial injection can be performed using a surgical approach (<a href="./references#CD013433-bbs2-0092" title="StammC , WestphalB , KleineHD , PetzschM , KittnerC , KlingeH , et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet2003;361:45-6.">Stamm 2003</a>), or transendocardial (<a href="./references#CD013433-bbs2-0086" title="PsaltisPJ , ZannettinoAC , GronthosS , WorthleySG . Intramyocardial navigation and mapping for stem cell delivery. Journal of Cardiovascular Translational Research2010;3:135-46.">Psaltis 2010</a>). </p> </section> <section id="CD013433-sec-0012"> <h3 class="title" id="CD013433-sec-0012">How the intervention might work</h3> <p>Some authors have suggested favourable effects of SCT for non‐ischaemic DCM, such as improvement in ventricular function, functional capacity, and quality of life (<a href="./references#CD013433-bbs2-0060" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34+ cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72.">Frljak 2018</a>; <a href="./references#CD013433-bbs2-0084" title="PoglajenG , ZemljičG , FrljakS , CerarA , AndročecV , SeverM , et al. Stem cell therapy in patients with chronic nonischemic heart failure. Stem Cells International2018;2018:6487812.">Poglagen 2018</a>). Although the mechanism of action of SCT is not completely understood, two main mechanisms may promote cardiac repair. The first is that transplanted cells are engrafted into the damaged myocardium, where they generate new myocardial tissue to replace the tissue that has been irreversibly lost. The second is that SCT acts by activating endogenous repair mechanisms (<a href="./references#CD013433-bbs2-0078" title="MenaschéP . Cell therapy trials for heart regeneration-lessons learned and future directions. Nature Reviews. Cardiology2018;15(11):659-71.">Menasché 2018</a>). This paracrine mechanism may produce stimulatory cytokines that increase vascularity, promote cardiomyocyte proliferation, limit or reduce fibrosis, or activate endogenous resident stem cells (<a href="./references#CD013433-bbs2-0041" title="BehfarA , Crespo-DiazR , TerzicA , GershBJ . Cell therapy for cardiac repair-lessons from clinical trials. Nature Reviews. Cardiology2014;11:232-46.">Behfar 2014</a>). SCT may also modulate the immune system, improve endothelial function, and reverse ventricular remodelling (<a href="./references#CD013433-bbs2-0066" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69:526-37.">Hare 2017</a>). </p> </section> <section id="CD013433-sec-0013"> <h3 class="title" id="CD013433-sec-0013">Why it is important to do this review</h3> <p>Both the European Society of Cardiology (ESC) in 2016 (<a href="./references#CD013433-bbs2-0085" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37:2129-200.">Ponikowski 2016</a>), and the American Heart Association (AHA) in 2013 (<a href="./references#CD013433-bbs2-0104" title="YancyC , JessupM , BozkurtB , ButlerJ , CaseyD , DraznerM , et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2013;128(16):e240-27.">Yancy 2013</a>), refer to this therapy as an evolving therapy, and more data are needed to establish a recommendation. In the last review published by the AHA regarding diagnosis and treatment of DCM, cell therapy is not supported for general management (<a href="./references#CD013433-bbs2-0045" title="BozkurtB , ColvinM , CookJ , CooperJT , DeswalA , FonarowGC , et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation2016;134:e579-646.">Bozkurt 2016</a>). </p> <p>Despite several clinical trials since the early 2010s, controversy remains regarding the role of SCT in DCM. For instance, SCT has not been included in major clinical practice guidelines (<a href="./references#CD013433-bbs2-0045" title="BozkurtB , ColvinM , CookJ , CooperJT , DeswalA , FonarowGC , et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation2016;134:e579-646.">Bozkurt 2016</a>; <a href="./references#CD013433-bbs2-0085" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37:2129-200.">Ponikowski 2016</a>). </p> <p>Systematic reviews of trials published before 2015 reported that, compared with conventional therapy, BMMC therapy had a moderate effect on left ventricular ejection fraction (LVEF) and left ventricular end‐systolic volume (LVESV) in non‐ischaemic DCM (<a href="./references#CD013433-bbs2-0101" title="WenY , DingJ , ZhangB , GaoQ . Bone marrow-derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy. A meta-analysis. European Journal of Clinical Investigation2018;48(4):e12894.">Wen 2018</a>). An earlier review concluded the bone marrow‐derived SCT may have some effect on mortality, a mild‐to‐moderate effect on LVEF increase within six months, but no improvement in functional capacity (<a href="./references#CD013433-bbs2-0074" title="LuY , WangY , LinM , ZhouJ , WangZ , JiangM , et al. A systematic review of randomised controlled trials examining the therapeutic effects of adult bone marrow-derived stem cells for non-ischaemic dilated cardiomyopathy. Stem Cell Research &amp; Therapy2016;7(1):186.">Lu 2016</a>). </p> <p>Since then, additional trials have been conducted using cell‐based therapies for treating non‐ischaemic heart failure (<a href="./references#CD013433-bbs2-0017" title="ButlerJ , EpsteinSE , GreeneSJ , QuyyumiAA , SikoraS , KimRJ , et al. Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II – a randomized trial. Circulation Research2017;120(2):332-40. ">Butler 2017</a>; <a href="./references#CD013433-bbs2-0018" title="ChenY , GaoEM , GaoCY , XuY , HuangKJ , NiuZM , et al. Effects of intracoronary autologous bone marrow mononuclear cells transplantation in patients with dilated cardiomyopathy. Zhonghua Xin Xue GuanBing Za Zhi2008;36(12):1087-91. ">Chen 2008</a>; <a href="./references#CD013433-bbs2-0060" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34+ cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72.">Frljak 2018</a>; <a href="./references#CD013433-bbs2-0066" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69:526-37.">Hare 2017</a>; <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>; <a href="./references#CD013433-bbs2-0097" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112:165-73.">Vrtovec 2013</a>; <a href="./references#CD013433-bbs2-0099" title="VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34(+) cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123:389-96.">Vrtovec 2018b</a>; <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>). The results of these trials provide a rationale for proposing this Cochrane Review to ascertain whether this intervention provides clinical benefits in people with DCM. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013433-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013433-sec-0014"></div> <p>To assess the efficacy and safety of SCT in adults with non‐ischaemic DCM.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013433-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013433-sec-0015"></div> <section id="CD013433-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013433-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included parallel‐arm individually randomized controlled trials (RCTs). Due to the specific nature of this intervention, we deemed cluster‐RCTs not feasible or cross‐over RCTs not appropriate designs to assess mid‐ or long‐term clinical effects of SCT. </p> <p>We did not restrict the study selection by publication status. We applied no restrictions on language of publication. </p> </section> <section id="CD013433-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials that evaluated adults aged 18 years or older with a diagnosis of non‐ischaemic DCM (as defined by the trial authors). </p> <p>We also included trials that evaluated both ischaemic and non‐ischaemic disease when specific data for the participants with non‐ischaemic DCM was available and could be extracted. </p> </section> <section id="CD013433-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials that compared:</p> <p> <ul id="CD013433-list-0001"> <li> <p>any type or delivery modality of SCT versus no intervention, sham intervention, or placebo (comparison 1); </p> </li> <li> <p>SCT versus therapy with G‐CSF or any other cytokine that stimulates the proliferation and differentiation of precursor cells in the bone marrow (but not comprising SCT) (comparison 2); </p> </li> <li> <p>different types or delivery modalities of SCT against each other (comparison 3).</p> </li> </ul> </p> <p>SCT in the context of this review may have consisted of a variety of modalities according to cell origin (autologous or heterologous), cell collection location (bone marrow‐derived cells or peripheral blood cells), type of cells infused (bone marrow‐derived mesenchymal stromal cells, mononuclear cells, myeloid cells, lymphoid cells, or mixed cells), delivery route (intracoronary, intramyocardial, or transendocardial), number of cell infusions (single or repeated infusions), volume of cells infused (high or low), and use of G‐CSF or cytokines for mobilization of stem cells. Although we had planned to take these variations into consideration by conducting subgroup analysis and investigation of heterogeneity, this was not done for the reasons noted below. </p> <p>We accepted any type of co‐intervention (guideline‐recommended pharmacological and device therapy or G‐CSF) when such co‐intervention was provided similarly to the experimental and control groups. </p> </section> <section id="CD013433-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>For trials that reported outcomes at several follow‐up points, we used the latest available time point for analysis of each outcome. </p> <p>We had planned that if a published trial did not report any one of these outcomes, we would contact the trial authors to ascertain whether the outcomes were measured but not reported. This situation did not occur. All included trials measured and reported at least one of the below outcomes. For those outcomes that were not reported in a usable format, we presented the results in a narrative form. </p> <p>When the information available in the article (main and secondary papers related to the same trial) was not detailed enough, whenever possible we used the information obtained in the ClinicalTrials.gov registry. Additionally, we contacted all study contact authors to complete information that was not available in other public sources. </p> <section id="CD013433-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013433-list-0002"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Safety, as indicated by periprocedural complications occurring at the time of bone marrow aspiration or administration of SCT or control. </p> </li> <li> <p>Safety, as documented adverse events (AE) (including tumorigenesis) within 30 days of treatment. </p> </li> </ul> </p> </section> <section id="CD013433-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013433-list-0003"> <li> <p>Health‐related quality of life, as measured using a validated tool (e.g. Kansas City Cardiomyopathy Questionnaire (KCCQ), Minnesota Living with Heart Failure Questionnaire (MLHFQ), and EuroQol‐5D Questionnaire (EQ‐5D). </p> </li> <li> <p>Performance status – functional class (New York Heart Association).</p> </li> <li> <p>Performance status – exercise tolerance (6‐minute walk test).</p> </li> <li> <p>Rehospitalizations.</p> </li> <li> <p>Heart failure.</p> </li> <li> <p>Ventricular arrhythmia.</p> </li> <li> <p>Complete atrioventricular block.</p> </li> <li> <p>Major adverse cardiovascular events (defined as non‐fatal stroke, non‐fatal myocardial infarction, or cardiovascular death). </p> </li> <li> <p>Change in left ventricular ejection fraction (LVEF).</p> </li> <li> <p>Change in left ventricular end‐systolic volume (LVESV).</p> </li> <li> <p>Change in left ventricular end‐diastolic volume (LVEDV).</p> </li> <li> <p>Change in plasma natriuretic peptide levels (brain natriuretic peptide [BNP] and N‐terminal pro b‐type natriuretic peptide [NT‐proBNP]). </p> </li> </ul> </p> <p>Although the scope of this review was to assess the clinical effects of SCT in people with DCM, we retained the outcome of LVEF because it is a widely reported surrogate for cardiac function. We also included the surrogate outcomes of LVESV and LVEDV because we consider these to be more meaningful than LVEF in this context. </p> <p>We have used one quality of life measure per study. For studies reporting two or more quality of life measures, we prioritized the measure with a specific instrument in people with cardiomyopathy over a generic one. </p> </section> </section> </section> <section id="CD013433-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013433-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We performed systematic electronic searches of the following bibliographic databases on 10 November 2020: </p> <p> <ul id="CD013433-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2020, Issue 11); </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 9 November 2020); </p> </li> <li> <p>Embase (Ovid, 1980 to 2020 week 45).</p> </li> </ul> </p> <p>We also conducted a search in ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>), and the WHO International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>), for ongoing or unpublished trials in May 2020. For the search in both registries, the keywords were 'cell therapy' and 'dilated cardiomyopathy.' </p> <p>We searched all databases from their inception to the present, with no restriction on language of publication or publication status. We found no retraction statements or errata for included studies. </p> <p>We adapted the preliminary search strategy for MEDLINE for use in the other databases (<a href="./appendices#CD013433-sec-0115">Appendix 1</a>). We applied the Cochrane sensitivity‐maximizing RCT filter to MEDLINE and adapted it to Embase, but not CENTRAL (<a href="./references#CD013433-bbs2-0072" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Lefebvre 2011</a>). </p> <p>We did not perform a separate search for adverse effects of interventions used for the treatment of DCM. We considered adverse effects described in included studies only. </p> </section> <section id="CD013433-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We also:</p> <p> <ul id="CD013433-list-0005"> <li> <p>searched the reference lists of all identified eligible papers and relevant systematic or narrative (or both) reviews as a complementary source for study identification and for validating our electronic search strategy; </p> </li> <li> <p>searched in Epistemonikos in order to identify systematic reviews on the topic (<a href="http://www.epistemonikos.org" target="_blank">www.epistemonikos.org</a>), as well as all primary studies included in them by using the tool 'matrix of evidence;' </p> </li> <li> <p>conducted a cross‐citation search in Google Scholar, using each included study as the index reference; </p> </li> <li> <p>contacted all authors of the included studies to request additional information.</p> </li> </ul> </p> </section> </section> <section id="CD013433-sec-0026"> <h3 class="title" id="CD013433-sec-0026">Data collection and analysis</h3> <section id="CD013433-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Three review authors (DP, FV, and GU) working in pairs independently screened the search results based on the title and abstract. At this stage, we coded decisions as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve.' We retrieved full‐text copied of the references deemed eligible (those coded as 'retrieve'), and the same authors independently confirmed eligibility based on the inclusion criteria. We resolved disagreements at either phase by consensus or by discussion with two other review authors (RD and EM). We coded reasons for exclusion of the ineligible studies. </p> <p>For data management, we used <a href="./references#CD013433-bbs2-0049" title="Veritas Health InnovationCovidence. Melbourne, Australia: Veritas Health Innovation, accessed prior to 1 July 2021. Available at covidence.org.">Covidence</a> as bibliographic management software to administer the results obtained from the search. </p> <p>We collated multiple reports of the same study so that each trial, rather than each report, was the unit of interest in the review. </p> <p>The search results as well as the decision made during the eligibility process are displayed in a PRISMA flow diagram (<a href="./references#CD013433-bbs2-0073" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100.">Liberati 2009</a>; Figure 5). </p> </section> <section id="CD013433-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used a standardized data collection form to extract data from each study in sufficient detail to design a comprehensive characteristics of studies table, risk of bias table, and to obtain the outcome data for the meta‐analysis. We piloted the data collection form before we agreed the final version of it to be used in the review. </p> <p>Three review authors (FV, DP, or GU) working in pairs independently extracted the data of each included study. In addition, a fourth author (RAD) checked all outcome data as well as risk of bias items of all studies. We resolved disagreements by consensus after discussion with participation of all members of the review team. </p> <p>We extracted the following study characteristics.</p> <p> <ul id="CD013433-list-0006"> <li> <p>Identification of the study and bibliographic references of all reports linked to the same study, as well as other secondary sources of relevant data (e.g. online supplements or trial registers). </p> </li> <li> <p>Eligibility criteria, as stated in the included studies.</p> </li> <li> <p>Participants: demographic (age, sex, and ethnicity), and relevant clinical data at baseline (those referred to severity of the disease and cardiac function, time from diagnosis to randomization, body mass index, smoking status, other relevant comorbidities, family history of DCM, and previous medical and device therapy). Also, the number of people randomized, the number who dropped out, and the number analyzed for each outcome. </p> </li> <li> <p>Intervention (SCT): detailed description of SCT (including cells origin (autologous or heterologous), cell collection location (bone marrow‐derived cells or peripheral blood cells), type of cells infused (mesenchymal stromal cells, mononuclear cells, myeloid cells, lymphoid cells, or mixed), mobilization of stem cells with cytokines (yes or no), delivery route (intracoronary, transendocardial, or intramyocardial), volume of cells administered, and number of cell infusions (single or repeated)). </p> </li> <li> <p>Control group: detailed description of the control group, and the corresponding category of the comparison of interest (comparison 1: no intervention, sham or placebo; comparison 2: treatment with cytokines (e.g. G‐CSF); and comparison 3: SCT). </p> </li> <li> <p>Outcomes: primary and secondary outcomes planned, measured, and reported, specifying the instrument of measure used and time points reported. Also, we collected the outcomes reported in other secondary sources (e.g. clinical trials) to assess the risk of selective reporting bias. </p> </li> <li> <p>Methods: study design, total duration of study, study setting and country, number of centres and location, period of study. </p> </li> <li> <p>Risk of bias assessment: details on method of treatment allocation and concealment, blinding of the intervention or the outcome assessor (or both), and dropouts (number, distribution, and reasons) and study population of analysis. </p> </li> <li> <p>Data on all relevant results reported (crude number of events or rates, mean values or mean change from baseline and the corresponding standard deviation (SD), and population analysed in each study arm). </p> </li> <li> <p>Funding and other conflicts of interest.</p> </li> </ul> </p> <p>We emailed all study contact authors requesting them to provide us with further details, as there were insufficiencies in all studies related to the outcome data or design features (or both). </p> <p>One review author (EM) transferred data into Review Manager 5 (<a href="./references#CD013433-bbs2-0088" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). Other members of the team (DP, FV, RAD, and GU) double‐checked data against the data extraction form and articles. </p> </section> <section id="CD013433-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <section id="CD013433-sec-0030"> <h5 class="title">Risk of bias in individual studies</h5> <p>Four review authors (FV, DP, GU and RAD) working in pairs independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013433-bbs2-0069" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). They resolved disagreements by discussion involving another two review authors (RD and EM). </p> <p>For this purpose, we explored the six specific domains.</p> <p> <ul id="CD013433-list-0007"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other potential sources of bias.</p> </li> </ul> </p> <p>For each trial, we first described the design characteristics relating to each domain and then judged the risk of bias associated with the main outcome. We used a nominal scale for the judgement: 'low,' 'high,' or 'unclear' risk of bias according to the criteria described in additional <a href="#CD013433-tbl-0004">Table 2</a>. </p> <div class="table" id="CD013433-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">The Cochrane tool for assessing risk of bias</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Domain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Random sequence generation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0008"> <li> <p>Low risk: if sequence generation was achieved using computer random number generator or a random numbers table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were also considered adequate if performed by an independent adjudicator. </p> </li> <li> <p>Unclear risk: if the method of randomization was not specified, but the trial was still presented as being randomized. </p> </li> <li> <p>High risk: if the allocation sequence was not randomized or only quasi‐randomized; we excluded these trials. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0009"> <li> <p>Low risk: if the allocation of participants was performed by a central independent unit, on‐site locked computer, identical‐looking numbered sealed envelopes, syringes prepared by an independent investigator. </p> </li> <li> <p>Unclear risk: if the trial was classified as randomized but the allocation concealment process was not described. </p> </li> <li> <p>High risk: if the allocation sequence was familiar to the investigators who assigned participants. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Blinding of participants and personnel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0010"> <li> <p>Low risk: if the participants and the personnel were blinded to intervention allocation and this was described </p> </li> <li> <p>Unclear risk: if the procedure of blinding was insufficiently described or not described at all. </p> </li> <li> <p>High risk: if blinding of participants and personnel was not performed.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Blinding of outcome assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0011"> <li> <p>Low risk: if it was mentioned that outcome assessors were blinded and this was described.</p> </li> <li> <p>Unclear risk: if it was not mentioned if the outcome assessors in the trial were blinded, or the extent of blinding was insufficiently described. </p> </li> <li> <p>High risk: if no blinding or incomplete blinding of outcome assessors was performed.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incomplete outcome data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0012"> <li> <p>Low risk: if missing data were unlikely to make treatment effects depart from plausible values. This could either be: there were no dropouts or withdrawals for all outcomes, or the numbers and reasons for the withdrawals and dropouts for all outcomes were clearly stated and could be described as being similar in both groups. Generally, the trial was judged at low risk of bias due to incomplete outcome data if dropouts were less than 5%. However, the 5% cut‐off is not definitive. </p> </li> <li> <p>Unclear risk: if there was insufficient information to assess whether missing data were likely to have induced bias on the results. </p> </li> <li> <p>High risk: if the results were likely to be biased due to missing data either because the pattern of dropouts could be described as being different in the 2 intervention groups or the trial used improper methods in dealing with the missing data (e.g. last observation carried forward). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selective outcome reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0013"> <li> <p>Low risk: if a protocol was published before or at the time the trial was begun and the outcomes specified in the protocol were reported on. If there was no protocol or the protocol was published after the trial had begun, reporting of all‐cause mortality and periprocedural complications (the 2 primary outcomes) will grant the trial a grade of low risk. </p> </li> <li> <p>Unclear risk: if no protocol was published and the 2 primary outcomes were not reported on. </p> </li> <li> <p>High risk: if the outcomes in the protocol were not reported on.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other risks of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0014"> <li> <p>Low risk: if the trial appeared free of other components (e.g. academic bias or for‐profit bias) that could have put it at risk of bias. </p> </li> <li> <p>Unclear risk: if the trial may or may not have been free of other components that could have put it at risk of bias. </p> </li> <li> <p>High risk: if there were other factors in the trial that could have put it at risk of bias (e.g. authors had conducted trials on the same topic, for‐profit bias, etc.). </p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Table adapted from Table 8.5.d: Criteria for judging risk of bias in the risk of bias assessment tool, in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013433-bbs2-0069" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). </p> </div> </div> <p>We contacted the principal investigator of all included studies to obtain or clarify key study features for a thorough risk of bias assessment. To June 2021, we obtained one response from <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>. </p> </section> <section id="CD013433-sec-0031"> <h5 class="title">Overall risk of bias</h5> <p> <ul id="CD013433-list-0015"> <li> <p>Low risk of bias: we classified the outcome result at overall 'low risk of bias' only if all the bias domains were judged at low risk of bias. For objective outcomes (e.g. mortality), we considered whether blinding was of relevance, and still categorized this at overall low risk of bias if a lack of blinding was unlikely to introduce bias. </p> </li> <li> <p>High risk of bias: we classified the outcome result at 'high risk of bias' if any bias domains (described above) were judged at 'unclear' or 'high risk of bias.' </p> </li> </ul> </p> <p>We generated a risk of bias table specifying these judgements, and provided a detailed justification for each judgement so that it was transparent and reproducible. Where information on risk of bias related to unpublished data or correspondence with a trialist, we specified this in the risk of bias table. </p> <p>When considering treatment effects across studies, we considered the risk of bias for the studies that contributed to that outcome. </p> </section> <section id="CD013433-sec-0032"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol (<a href="./references#CD013433-bbs2-0105" title="Diaz-NavarroR , UrrútiaG , ClelandJG , PoloniD , VillagranF , BangdiwalaS , et al. Stem cell therapy for dilated cardiomyopathy. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD013433. [DOI: 10.1002/14651858.CD013433]">Diaz‐Navarro 2019</a>), and reported deviations from it in the <a href="#CD013433-sec-0122">Differences between protocol and review</a> section. </p> </section> </section> <section id="CD013433-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous data for each arm in a particular study as a proportion or risk and the treatment effect as a risk ratio (RR) with 95% confidence intervals (CIs), calculated using Mantel‐Haenszel methods. </p> <p>We expressed continuous data for each arm in a particular study as a mean and SD, and the treatment effect as the mean difference (MD) if outcomes were measured in the same way across trials. We preferred the mean change difference over the difference in the final means if available. For studies that only reported baseline and endpoint data, when possible, we calculated the SD of the mean change from baseline based on reported CIs or P values, and used these values in the analysis. We presented studies with insufficient information to calculate the SD (e.g. studies that only report endpoint mean values) in combined analyses (assuming the differences in mean final values will on average be the same as the differences in mean change scores), as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013433-bbs2-0068" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from  training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p>For studies that measured continuous outcomes using different tools, for example for health‐related quality of life, we expressed the treatment effect as the standardized mean difference (SMD). We have adopted the following arbitrary subjective terminology for the interpretation of SMD, based on seminal suggestions by <a href="./references#CD013433-bbs2-0048" title="CohenJ . Statistical Power Analysis in the Behavioural Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc, 1988.">Cohen 1988</a>: if effect size is about 0.8 then 'large,' if effect size about 0.5 then 'medium,' and if effect size about 0.2 then 'small.' </p> <p>Some studies presented results for continuous outcomes (especially LVEF, LVESV, and LVEDV) only in figures or graphs. To retrieve the raw data for use in the meta‐analyses, we used a specialized software (<a href="http://getdata-graph-digitizer.com/" target="_blank">GetData Graph Digitizer 2.26</a>). </p> </section> <section id="CD013433-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>We only included parallel‐group individually randomized RCTs.</p> <p>Where multiple trial intervention groups were reported in a single trial, we included only the relevant groups. That was the case for <a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>, a four‐arm trial that contributed both to comparison 1 and 2 (see details of the arms used in each comparison in the <a href="./references#CD013433-sec-0131" title="">Characteristics of included studies</a> table). In <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>, we merged the two SCT arms for the comparison of SCT versus control for all‐cause mortality to avoid double‐counting of control group participants (<a href="./references#CD013433-bbs2-0051" title="DeeksJJ , HigginsJP , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Deeks 2017</a>). Instead, for LVEF outcome, we used data from one of these arms as the study provided only specific data for each group (mean and SD). However, we also alternatively calculated the pooled effect using the other arm to ensure that the result did not change. </p> </section> <section id="CD013433-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the principal investigators of all studies to request mean change difference and SD for several relevant outcomes where these data were not available or could not be calculated. To June 2021, we had not received any response. </p> <p>We used Review Manager 5 to calculate missing SDs using other data from the trial (<a href="./references#CD013433-bbs2-0088" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>), such as CIs or standard error (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>). </p> <p>There were no major issues with missing data in the review. Therefore, we did not perform a sensitivity analysis as originally planned neither did we make any imputations on these data in our primary analysis. </p> </section> <section id="CD013433-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We inspected forest plots visually to consider the direction and magnitude of effects and the degree of overlap between CIs. Second, we considered the P value from the Chi² test (threshold P &lt; 0.10) to address the presence of statistical heterogeneity. We also used the I² statistic to quantify statistical heterogeneity not attributable to chance among the trials in each analysis but acknowledge that there is substantial uncertainty in the value of the I² statistic when there is a small number of studies. We followed the recommendations for thresholds in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013433-bbs2-0051" title="DeeksJJ , HigginsJP , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Deeks 2017</a>): </p> <p> <ul id="CD013433-list-0016"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90% may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: may represent considerable heterogeneity.</p> </li> </ul> </p> <p>No meta‐analysis was avoided by this reason (<a href="./references#CD013433-bbs2-0051" title="DeeksJJ , HigginsJP , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Deeks 2017</a>). In fact, there was considerable heterogeneity in most outcomes analyzed, which was considered when rating the quality of the available evidence of the effects of SCT. </p> <p>Contrary to what was initially planned, we could not explore possible causes of considerable heterogeneity by prespecified subgroup analysis. </p> </section> <section id="CD013433-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>As we were unable to pool more than 10 trials in the meta‐analyses, we did not use a funnel plot to explore possible small‐study biases for the primary outcomes, neither did we carried out the Harbord test to test asymmetry for dichotomous outcomes (<a href="./references#CD013433-bbs2-0064" title="HarbordRM , EggerM , SterneJA . A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443-57.">Harbord 2006</a>), or regression asymmetry test for continuous outcomes (<a href="./references#CD013433-bbs2-0055" title="EggerM , SmithGD , SchneiderM , ChristophM . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315:629.">Egger 1997</a>). </p> </section> <section id="CD013433-sec-0038"> <h4 class="title">Data synthesis</h4> <p>Whenever possible, we undertook meta‐analyses according to the recommendations stated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013433-bbs2-0051" title="DeeksJJ , HigginsJP , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Deeks 2017</a>). We used the Cochrane statistical software Review Manager 5 to analyse data (<a href="./references#CD013433-bbs2-0088" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p>We assessed the intervention effects using random‐effects meta‐analyses due to the high heterogeneity we found in most outcomes (<a href="./references#CD013433-bbs2-0052" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DerSimonian 1986</a>). Even for those outcomes where we did not detect heterogeneity, we used this approach because it was more conservative. </p> </section> <section id="CD013433-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Contrary to what we had initially planned, subgroup analyses were not carried out as they were considered uninformative. On the one hand, the absence of a global effect in almost all the outcomes analysed and, on the other, the small number of available studies (fewer than three) in some category of all the subgroup analyses, prevented this type of analysis. </p> </section> <section id="CD013433-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We only carried out sensitivity analyses for an exploratory purpose to assess the influence of a particular study that showed very inconsistent results (outliers) with the rest in the combined analysis, and the degree of heterogeneity caused by it. These analyses are not shown in the review. </p> </section> <section id="CD013433-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a summary of findings table for comparison 1 (SCT versus control) and comparison 2 (SCT plus G‐CSF versus G‐CSF), using the following outcomes included in the review: all‐cause mortality; safety, as indicated by periprocedural complications; health‐related quality of life; performance status (exercise tolerance); ventricular arrhythmias; and MACE<i>.</i> For each outcome, we presented data at the longest follow‐up that was available for each study. </p> <p>We have not created a summary of findings table for comparison 3 (different types or delivery modalities of SCT against each other) as this comparison included four RCTs that compared different aspects related to SCT delivery that could not be combined. </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the evidence as it related to the studies that contributed data to the meta‐analyses for the prespecified outcomes. We used methods and recommendations described in Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013433-bbs2-0091" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Schünemann 2017</a>), using GRADEpro GDT software (<a href="./references#CD013433-bbs2-0062" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed prior to 11 September 2019. Available at gradepro.org.">GRADEpro GDT</a>). </p> <p>We justified all decisions to downgrade the certainty of the evidence using footnotes and made comments to aid reader's understanding of the review where necessary. </p> <p>Several review authors made judgements about the certainty of evidence after discussion among the team (DP, FV, GU, RAD, RD, EM, and SB). We justified, documented, and incorporated into reporting of results all judgements for each outcome. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013433-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013433-sec-0042"></div> <section id="CD013433-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD013433-sec-0044"> <h4 class="title">Results of the search</h4> <p>We identified 462 records from the electronic database searches and 39 records from other sources (clinical trials registers). Deduplication and removal of all clearly irrelevant references excluded 114 references. Initial screening of the remaining 387 citations against inclusion criteria excluded a further 337 references. Of the remaining 50 citations, we subsequently excluded 18 references, as they did not fully meet the inclusion criteria or they were abstracts of potentially relevant studies that never were published as a full paper after a sufficient time (see <a href="#CD013433-sec-0046">Excluded studies</a>). </p> <p>Four other relevant studies were identified in ClinicalTrials.gov that met the eligibility criteria. All of them are still ongoing or have been completed but not yet published (<a href="./references#CD013433-bbs2-0031" title="NCT01957826. Mesenchymal stem cells for idiopathic dilated cardiomyopathy. clinicaltrials.gov/ct2/show/NCT01957826 (first received 8 October 2013). ">NCT01957826</a>; <a href="./references#CD013433-bbs2-0032" title="NCT02033278. Infusion intracoronary of mononuclear autologous adult no expanded stem cells of bone marrow on functional recovery in patients with idiopathic dilated cardiomyopathy and heart failure. clinicaltrials.gov/ct2/show/NCT02033278 (first received 10 January 2014). ">NCT02033278</a>; <a href="./references#CD013433-bbs2-0033" title="NCT02293603. Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC). clinicaltrials.gov/ct2/show/NCT02293603 (first received 18 November 2014). ">NCT02293603</a>; <a href="./references#CD013433-bbs2-0034" title="NCT03797092. Stem cell therapy in non-ischemic non-treatable dilated cardiomyopathies II: a pilot study. clinicaltrials.gov/ct2/show/NCT03797092 (first received 8 January 2019). ">NCT03797092</a>), these are shown in the <a href="./references#CD013433-sec-0133" title="">Characteristics of ongoing studies</a> table. </p> <p>The remaining 28 citations described 13 individual RCTs (see <a href="./references#CD013433-sec-0131" title="">Characteristics of included studies</a> table). Two identical phase II trials (Catheter‐DCM and IMPACT‐DCM) that run in parallel and compared SCT (a different modality each) versus control (same type) in a mixed population of people with ischaemic and non‐ischaemic DCM were published in the same article (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>). For the purpose of this review, both experimental (SCT) and control groups were respectively merged, and the study included as one study within comparison 1 (using only data of the people with non‐ischaemic DCM). </p> <p>A summary of study classification is displayed in a PRISMA flow diagram (<a href="#CD013433-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013433-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD013433-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD013433-sec-0045"> <h4 class="title">Included studies</h4> <p>Thirteen studies met the inclusion criteria for this review, including 762 randomized participants (452 bone marrow‐derived stem/progenitor cells and 310 controls) who were assessed for the primary outcomes of the study (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>; <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>; <a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a>; <a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>; <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>; <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>; <a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a>; <a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a>; <a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>; <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>). See <a href="./references#CD013433-sec-0131" title="">Characteristics of included studies</a> table for a summary of study participants and other characteristics of the studies. </p> <p>Mean size of the included studies was 60 (ranging from 22 (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>) to 160 (<a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>), with a median of 55 participants. The mean age of participants ranged from 45 to 58.5 years, and the proportion of men ranged from 50% to 89%. All trials were presented as full journal articles, except one in a short format (<a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>). Only two trials were multicentre (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>). Studies were based worldwide, including the UK (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>), Slovenia (<a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>; <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>; <a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a>; <a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a>), the US (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>), Brazil (<a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>; <a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a>), India (<a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>), and China (<a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>; <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>). All studies were published in English language except two that included publications in Chinese (<a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>), which were translated into English for this review. </p> <p>Twelve studies included participants with congestive heart failure (CHF) secondary to DCM where ischaemic aetiology was excluded. <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a> included a mixed population but results were presented separately for participants with non‐ischaemic DCM. In all studies, participants remained with an optimal standard pharmacological treatment including beta‐blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, spironolactone, digoxin, diuretics, and hydralazine plus nitrates. </p> <p>Total duration of follow‐up was six months in two studies (<a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a>), 12 months in seven studies (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>; <a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a>; <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>; <a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a>; <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>), 24 months in two studies (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>), three years in one study (<a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>), and five years in one study (<a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>). </p> <p>The 13 included studies accounted for 29 study arms (11 RCTs with two arms, one with three arms, and one with four arms). </p> <p>According to the funding source, only one study declared a private funding (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>) or a mixed public and private funding (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>), while six had public or governmental funding, and two non‐profit funding. The three studies set in China did not report this information (<a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>; <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>). </p> <p>All but four studies (<a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>; <a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>; <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>) were registered in ClinicalTrials.gov.  </p> <p>According to the comparison group:</p> <p> <ul id="CD013433-list-0017"> <li> <p>eight RCTs compared SCT versus no intervention or sham (comparison 1): <a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>; <a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a>; <a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>; <a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>; and <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>; </p> </li> <li> <p>three RCTs compared SCT plus G‐CSF versus G‐CSF (comparison 2): <a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>; and <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>; </p> </li> <li> <p>four RCTs compared SCT versus SCT (comparison 3): <a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>; <a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a>; <a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a>, and <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>). A summary of the specific comparisons within this group is presented in <a href="#CD013433-tbl-0005">Table 3</a>. </p> </li> </ul> </p> <div class="table" id="CD013433-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of comparison 3</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Details on the specific comparison</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Autologous vs allogeneic mesenchymal stem cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intracoronary vs transendocardial delivery of stem cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Repetitive vs single dose of stem cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mononuclear vs mesenchymal bone marrow stem cells</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD013433-sec-0046"> <h4 class="title">Excluded studies</h4> <p>Among the 18 papers excluded after reading the full text, 15 were studies with serious doubts and one was a trial registered in ClinicalTrials.gov. These were excluded due to a diversity or reasons: </p> <p> <ul id="CD013433-list-0018"> <li> <p>wrong design (<a href="./references#CD013433-bbs2-0014" title="BartolucciJ , VerdugoFJ , CarrionF , AbarzúaE , GosetC , LamichR , et al. Long-term results of intracoronary transplantation of autologous bone marrow cells in dilated cardiomyopathy [Resultados a largo plazo deltrasplante intracoronario de células mononucleares de médula ósea autólogas enpacientes con cardiopatía dilatada de diversa etiología]. Revista Médica de Chile2015;143(4):415-23. ">Bartolucci (INNOVA) 2015</a>; <a href="./references#CD013433-bbs2-0016" title="BocchiEA , BacalF , GuimaraesG , MendroniA , MocelinA , FilhoAE , et al. Granulocyte-colony stimulating factor or granulocyte-colony stimulating factor associated to stem cell intracoronary infusion effects in non ischemic refractory heart failure. International Journal of Cardiology2010;138(1):94-7. [DOI: dx.doi.org/10.1016/j.ijcard.2008.06.002]">Bocchi 2010</a>; <a href="./references#CD013433-bbs2-0017" title="ButlerJ , EpsteinSE , GreeneSJ , QuyyumiAA , SikoraS , KimRJ , et al. Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II – a randomized trial. Circulation Research2017;120(2):332-40. ">Butler 2017</a>; <a href="./references#CD013433-bbs2-0018" title="ChenY , GaoEM , GaoCY , XuY , HuangKJ , NiuZM , et al. Effects of intracoronary autologous bone marrow mononuclear cells transplantation in patients with dilated cardiomyopathy. Zhonghua Xin Xue GuanBing Za Zhi2008;36(12):1087-91. ">Chen 2008</a>; <a href="./references#CD013433-bbs2-0019" title="Fischer-RasokatU , AssmusB , SeegerFH , HonoldJ , LeistnerD , FichtlschererS , et al. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circulation. Heart Failure2009;2(5):417-23. ">Fischer‐Rasokat 2009</a>; <a href="./references#CD013433-bbs2-0020" title="HuangRC , YaoK , LiYL , ZhangYQ , XuSK , ShiHY , et al. Transplantation of autologous bone marrow mononuclear cells on patients with idiopathic dilated cardiomyopathy: early results on effect and security. Zhonghua Xin Xue Guan Bing Za Zhi2006;34(2):111-3. ">Huang 2006</a>; <a href="./references#CD013433-bbs2-0026" title="TompkinsBA , RiegerAC , FloreaV , BanerjeeMN , NatsumedaM , NighED , et al. Comparison of mesenchymal stem cell efficacy in ischemic versus nonischemic dilated cardiomyopathy. Journal of the American Heart Association2018;7(14):e008460. ">Tompkins 2018</a>); </p> </li> <li> <p>wrong population (<a href="./references#CD013433-bbs2-0015" title="BartolucciJ , VerdugoFJ , GonzálezPL , LarreaRE , AbarzuaE , GosetC , et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial [Randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circulation Research2017;121(10):1192-204. ">Bartolucci (RIMECARD) 2017</a>; <a href="./references#CD013433-bbs2-0022" title="MiyagawaS , DomaeK , YoshikawaY , FukushimaS , NakamuraT , SaitoA , et al. Phase I clinical trial of autologous stem cell-sheet transplantation therapy for treating cardiomyopathy. Journal American Heart Association2017;6(4):e003918. ">Miyagawa 2017</a>; <a href="./references#CD013433-bbs2-0023" title="NCT02256501. Intracoronary transplantation of bone marrow derived mononuclear cells in pediatric cardiomyopathy. clinicaltrials.gov/ct2/show/NCT02256501 (first received 3 October 2014). ">NCT02256501</a>; <a href="./references#CD013433-bbs2-0024" title="PerinEC , BorowKM , SilvaGV , DeMariaAN , MarroquinOC , HuangPP , et al. A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circulation Research2015;117(6):576-84. ">Perin (REVASCOR) 2015</a>; <a href="./references#CD013433-bbs2-0025" title="PremerC , BlumA , BellioMA , SchulmanIH , HurwitzBE , ParkerM , et al. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine2015;2(5):467-75. ">Premer 2015</a>; <a href="./references#CD013433-bbs2-0027" title="XiaoWT , GaoLJ , GaoCY , GaoYJ , DaiGY , LiMW , et al. Comparative study on the efficacy of intracoronary infusion with various types of autologous bone marrow stem cells for patients with dilated cardiomyopathy. Zhonghua Xin XueGuan Bing Za Zhi2012;40(7):575-8. ">Xiao 2012a</a>; <a href="./references#CD013433-bbs2-0028" title="XiaoWT , GaoCY , DaiGY , LiMW , WangXP , LiuHZ , et al. Autologous bone marrow mesenchymal stem cells for myocardial renewal and repair. Chinese Journal of Tissue Engineering Research2012;16(27):5081-6. ">Xiao 2012b</a>; <a href="./references#CD013433-bbs2-0029" title="YauTM , PaganiFD , ManciniDM , ChangHL , LalaA , WooYJ , et al. Intramyocardial injection of mesenchymal precursor cells and successful temporary weaning from left ventricular assist device support in patients with advanced heart failure: a randomized clinical trial. JAMA2019;321(12):1176-86. ">Yau 2019</a>; <a href="./references#CD013433-bbs2-0030" title="ZemljicG , PoglajenG , SeverM , CukjatiM , FrljakS , AndrocecV , et al. Electroanatomic properties of the myocardium predict response to CD34+ cell therapy in patients with ischemic and nonischemic heart failure. Journal of Cardiac Failure2017;23(2):153-60. ">Zemljic 2017</a>). </p> </li> </ul> </p> <p>One additional study (two references) was published in abstract format only, and although it appeared to meet the inclusion criteria, it did not contain sufficient data for inclusion. As it was published in 2011 and there has been no full paper published, we decided to exclude it from the review (<a href="./references#CD013433-bbs2-0021" title="KakuchayaT , GolukhovaE , EremeevaM , ChigogidzeN , AslanidiI , NikitinaT , et al. Bone-marrow progenitor stem cells for the treatment of patients with congestive heart failure of different etiology in a placebo controlled clinical trial. Interactive Cardiovascular and Thoracic Surgery2011;12:568. KakuchayaT , GolukhovaE , EremeevaM , ChigogidzeN , AslanidiI , ShurupovaI , et al. Accurate design of randomized placebo-controlled clinical trials for assessment of stem cell effects on cardiac regeneration. European Heart Journal2011;32:290. ">Kakuchaya 2011</a>).  </p> </section> </section> <section id="CD013433-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary of the risk of bias in individual studies is given below and in <a href="#CD013433-fig-0002">Figure 2</a>. Judgements about each risk of bias item can be seen in <a href="#CD013433-fig-0003">Figure 3</a>. Further details of our assessment of risk of bias can be found in the <a href="./references#CD013433-sec-0131" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD013433-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013433-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD013433-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013433-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>We considered only one trial to have a low risk of bias across all domains (<a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>). </p> <p>Due to the specific nature of the intervention (SCT), the most problematic item was related to selective reporting with major inconsistencies between the ClinicalTrials.org record and the publication, and with blinding of study personnel and participants (performance bias). Numerous shortcomings in the reporting of most of the included studies did not allow an adequate assessment of some of the following items. However, the additional information available in ClinicalTrials.gov and in online appendices or supplements, in some cases, allowed a more precise description and risk of bias assessment. </p> <p>Frequently, the format of the continuous data available was not ideal for use in the meta‐analysis. We would have preferred to evaluate the mean change difference, since, as most of the studies were small, there were frequently baseline differences. However, limitations in the reporting of the studies made it impossible to obtain the necessary data to calculate this estimate, so that differences in the final means and difference in the mean changes were combined. Furthermore, in various studies, the final mean and the associated SD was obtained from graphs using specialized software (<a href="http://getdata-graph-digitizer.com/" target="_blank">GetData Graph Digitizer 2.26</a>). </p> <section id="CD013433-sec-0048"> <h4 class="title">Allocation</h4> <p>Only four studies provided details of randomization methods with a low risk of bias from random sequence generation (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>; <a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a>). All four used randomization codes generated electronically. The remaining studies provided no details about the method used to generate the random sequence and, therefore, we judged risk of bias as unclear. </p> <p>Only one study described appropriate methods of allocation concealment with a low risk of bias (<a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>), while all other trials had unclear allocation concealment. </p> </section> <section id="CD013433-sec-0049"> <h4 class="title">Blinding</h4> <p>In four studies, participants randomized to the control group received a placebo injection (sham) (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>; <a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>). We judged these trials at a low risk of performance bias. We considered all other trials  at high risk of performance bias due to the open‐label design. </p> <p>For detection bias, 10 studies were at low risk of bias (four for using sham as a control (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>; <a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>), and six open‐label trials that reported blinding of outcome assessors (<a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>; <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>; <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>; <a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a>; <a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a>). The three other studies were at high risk of detection bias (<a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a>; <a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>; <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>). </p> </section> <section id="CD013433-sec-0050"> <h4 class="title">Incomplete outcome data</h4> <p>Four trials had a high risk of attrition bias due to imbalances in the distribution of withdrawals and participants lost to follow‐up between groups, without a proper statistical handling of missing data in the analysis (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a>; <a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>; <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>). Five studies were at unclear risk of attrition bias, due to incomplete or confusing information about number of participants lost to follow‐up or the statistical methods used to deal with it (or both) (<a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>; <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>; <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>; <a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>). Four studies were at low risk of attrition bias (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>; <a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a>; <a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a>). </p> </section> <section id="CD013433-sec-0051"> <h4 class="title">Selective reporting</h4> <p>Three studies were at high risk of reporting bias, but reasons differed. One study only specified the primary endpoint at ClinicalTrials.gov (<a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a>), while in two studies there were several important inconsistencies between the information provided in ClinicalTrials.gov and the final publication related to the number of participants, the time point for the outcomes, the completion date, and the outcomes that were planned and finally reported (<a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>; <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>). We suspect that participants reported in <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a> were also included in the <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a> analysis. We contacted the corresponding author by email but have received no response. Four trials were not previously registered in a public register and, therefore, the risk of reporting bias was unclear (<a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>; <a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>; <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>). Finally, six studies were at low risk of reporting bias as they had been registered at ClinicalTrials.gov and all outcomes reported corresponded to those registered (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>; <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>; <a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a>; <a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a>). </p> </section> <section id="CD013433-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p>There is an issue of lack of transparency that affects several of the studies that did not report the funding sources nor were registered in a public trial registry. However, in the specific context of cell therapy research, we think that even supposedly non‐commercial studies are also not free from bias. For this reason, this criterion was ultimately not used in the risk of bias summary and risk of bias tables. </p> </section> </section> <section id="CD013433-sec-0053"> <h3 class="title" id="CD013433-sec-0053">Effects of interventions</h3> <p>See: <a href="./full#CD013433-tbl-0001"><b>Summary of findings 1</b> Stem cell therapy compared to control for dilated cardiomyopathy</a>; <a href="./full#CD013433-tbl-0003"><b>Summary of findings 2</b> Stem cell therapy (any type) compared to peripheral therapy with granulocyte colony‐stimulating factor for dilated cardiomyopathy</a> </p> <p>The effects of the intervention (SCT) for each outcome analysed are presented below. Results are discussed separately depending on the type of comparison (control): </p> <p> <ul id="CD013433-list-0019"> <li> <p>comparison 1: SCT versus no intervention or sham (<a href="./full#CD013433-tbl-0001">summary of findings Table 1</a>); </p> </li> <li> <p>comparison 2: SCT versus G‐CSF (<a href="./full#CD013433-tbl-0003">summary of findings Table 2</a>). </p> </li> </ul> </p> <p>Where possible, the results of the meta‐analysis are presented or, when not possible, narratively. </p> <p>For comparison 3 (different types or delivery modalities of SCT against each other), the results are presented narratively, since the meta‐analysis did not apply as the they were very diverse and not comparable. </p> <section id="CD013433-sec-0054"> <h4 class="title">Primary outcomes</h4> <section id="CD013433-sec-0055"> <h5 class="title">All‐cause mortality</h5> <section id="CD013433-sec-0056"> <h6 class="title">Comparison 1: stem cell therapy versus control (no intervention or sham)</h6> <p>All studies comparing SCT versus control included mortality as an outcome, although it was not a primary outcome in any of them. We excluded one study that reported mortality with zero events in both arms in the non‐ischaemic population from the analysis (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>). Mortality rate was 16.2% (32/198) in participants who received SCT, similar to that observed in participants who received no cells (19.6%, 32/163) (RR 0.84, 95% CI 0.54 to 1.31; I² = 0%; studies = 7; participants = 361; very low‐certainty evidence; <a href="./references#CD013433-fig-0004" title="">Analysis 1.1</a>). </p> <p>Despite the absence of statistical heterogeneity observed in the analysis, mortality at one year ranged from 0% (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>) to 35.0% (<a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>) in the control group, and from 0% (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>) to 36.8% (<a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a> in the SCT group. This variation suggests there were important differences in study population (baseline risk) across studies. For a better understanding of the differences observed among studies, mortality rates of all studies included in the review are displayed in <a href="./full#CD013433-tbl-0002">Table 1</a>. </p> <p>In summary, we are uncertain whether SCT may reduce mortality in people with DCM compared to control (no intervention or sham) due to the very low‐certainty evidence that is available. </p> </section> <section id="CD013433-sec-0057"> <h6 class="title">Comparison 2: stem cell therapy versus granulocyte‐colony stimulating factor</h6> <p>The three studies comparing SCT versus G‐CSF assessed mortality as an outcome. One four‐arms study already included in comparison 1 is also included in this comparison (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>). For this comparison we used the data form 'peripheral G‐CSF' as the control group. </p> <p>Mortality rate was 12.3% (12/98) in participants who received cell therapy plus G‐CSF, lower than that observed in participants who only received G‐CSF (30.3%, 27/97) (RR 0.46, 95% CI 0.16 to 1.31; I² = 39%; participants = 195; studies = 3; very low‐certainty evidence; <a href="./references#CD013433-fig-0010" title="">Analysis 2.1</a>). Although global heterogeneity is low, there is a discrepancy produced by <a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> where two deaths were observed in the SCT group and none in the control, while in the two other studies mortality was reduced in the SCT group. Had we excluded this study from the meta‐analysis, the pooled estimate would clearly favour SCT. </p> <p>In summary, we are uncertain whether SCT may reduce mortality in people with DCM compared to G‐CSF due to overall very low‐certainty evidence that is available. </p> </section> <section id="CD013433-sec-0058"> <h6 class="title">Comparison 3: different types or delivery modalities of stem cell therapies against each other </h6> <p>Of the four studies comparing different types or delivery modalities of SCT, three assessed mortality at one year. In <a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>, there were only two deaths among 34 participants treated with SCT (5.9%). These occurred in the group receiving autologous mesenchymal stem cells versus none in the allogeneic group. In <a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a>, only 1/60 participant with SCT (mononuclear cells) died (1.7%). The participant was assigned to single SCT; the comparator group received repetitive SCT. In <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>, only 1/31 participants receiving SCT (3.2%) died at one year. The participant was assigned to BMMCs; the comparator group received bone marrow mesenchymal stem cells (BMSC). </p> </section> </section> <section id="CD013433-sec-0059"> <h5 class="title">Procedural complications (safety)</h5> <p>Ten studies assessed the composite outcome of procedural complications (safety). However, the definition of the outcome varied widely between studies. For this reason, we reported the outcome narratively. </p> <section id="CD013433-sec-0060"> <h6 class="title">Comparison 1: stem cell therapy versus control (no intervention or sham)</h6> <p><a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> assessed the safety of the SCT infusion by measurement of creatine kinase (CK) and troponin T concentrations 12 hours after infusion and procedural complications. There were no cases of distal coronary artery occlusion, acute cardiac dysfunction, ventricular arrhythmia, or significant CK or troponin T release occurred after the procedure. One participant experienced a localized coronary dissection during SCT infusion. </p> <p>The primary objective of the studies run by <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a> (IMPACT‐DCM and Catheter‐DCM) was to assess the safety of SCT (ixmyelocel‐T) administered via mini‐thoracotomy (IMPACT‐DCM) or intramyocardial catheter (Catheter‐DCM) injections. The study reported AEs per participant at days zero to five (perisurgical period), and at days six to 730 after the procedure. The five most common AEs in the SCT (ixmyelocel‐T) groups in the perisurgical period (day zero to five), according to what was stated by the trial authors, were hypotension, nausea, constipation, hyperglycaemia, and hypertension. Surgical delivery of SCT (ixmyelocel‐T) via mini‐thoracotomy was associated with a higher incidence of serious adverse events (SAEs) in the perisurgical period (day zero to five) (6.71 AEs/participant). This finding was not observed when SCT was delivered via catheter (0.93 AEs/participant). After the procedure (days six to 730), the number of AEs per participant in both SCT groups was comparable (8.21 via mini‐thoracotomy versus 6.27 AEs/participant via catheter). </p> <p><a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a> reported no SAEs were directly related to cell injection during the trial. They provided no definition of AEs. </p> <p><a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a> assessed procedural safety as a secondary outcome. Authors reported that four participants died in the first month after the procedure. Two died of refractory cardiogenic shock in the first 72 hours postoperatively, one died on the 15th postoperative day due to incessant ventricular tachycardia, and one died on the 28th postoperative day due to heart failure that was refractory to treatment. </p> <p><a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a> stated "this study establishes the long‐term safety of this therapy in dilated cardiomyopathy." However, they provided no definition or specific data. </p> <p><a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a> concluded that cell transplantation was safe. There was no embolism, arrhythmia, or other negative clinical events throughout the study. </p> <p><a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a> observe no AEs such as fever, allergic reaction, myocardial infarction, embolism, and tumour formation related with the procedure. </p> <p><a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a> defined procedural complications as any new‐onset ventricular arrhythmia, conduction disturbance, distal embolization, thrombus formation, and injury of the coronary artery related to the cell injection procedure. However, the study did not report this outcome. </p> </section> <section id="CD013433-sec-0061"> <h6 class="title">Comparison 2: stem cell therapy versus granulocyte‐colony stimulating factor</h6> <p>Only one study out of three reported on this outcome within this comparison. In <a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>, one participant experienced a localized coronary dissection during STC infusion. There were no complications or AEs associated with G‐CSF therapy. </p> </section> <section id="CD013433-sec-0062"> <h6 class="title">Comparison 3: different types or delivery modalities of stem cell therapies against each other </h6> <p><a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a> defined SAE as "any serious event that may result in persistent or significant disability or incapacity and included death, heart transplantation, ventricular assist device implantation, sustained ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation), and heart failure exacerbation requiring hospitalization." There were 10 SAEs in 60 participants, the most frequent being heart failure worsening (7%) and sustained ventricular arrhythmia (5%). The number of SAEs did not differ between the repetitive versus the single‐dose SCT groups. </p> <p>In <a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>, the primary safety endpoint was the incidence of any treatment‐emergent SAE occurring within 30 days of treatment. Secondary safety endpoints included other AEs. There were no 30‐day treatment‐emergent SAEs among the 34 study participants. At the end of follow‐up (one year), SAE incidence was 28.2% with allogeneic mesenchymal stem cells versus 63.5% with autologous mesenchymal stem cells. </p> </section> </section> </section> <section id="CD013433-sec-0063"> <h4 class="title">Secondary outcomes</h4> <section id="CD013433-sec-0064"> <h5 class="title">Health‐related quality of life</h5> <p>Six studies reported health‐related quality of life. Four used the MLHFQ (<a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>; <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>; <a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a>), and two used the KCCQ (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>). In addition, <a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> also used the generic European Quality of Life‐5 Dimensions (EQ5D). For the pooled analysis, KCCQ was preferred over EQ5D. We used the KCCQ clinical summary score over the overall summary. </p> <p>The pooled analysis (only for comparison 1) combines different HRQoL tools, and methods to estimate treatment effect (mean change differences and difference in final means (<a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>). We obtained the raw data from figures using a specialized software for one study (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>). One study reported trimmed means instead of means (<a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>). In <a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a>, the SD of the difference in mean change differences was imputed from <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a> (baseline mean values were very similar in both studies). </p> <p>In the analysis of quality of life outcomes, we converted MLHFQ scores to negative values in order to include these in a meta‐analysis with other measures on different scales using the SMD. </p> <section id="CD013433-sec-0065"> <h6 class="title">Comparison 1: stem cell therapy versus control (no intervention or sham)</h6> <p>We are uncertain whether SCT improves health‐related quality of life compared to control (no intervention or sham) (SMD 0.62, 95% CI 0.01 to 1.23; I² = 80%; studies = 5, participants = 272; very low‐certainty evidence; <a href="./references#CD013433-fig-0005" title="">Analysis 1.2</a>). </p> <p>The substantial heterogeneity observed in this analysis was attributable to <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>, a robust trial with a relatively large sample size, which found no beneficial effect of SCT on health‐related quality of life (measured with the MLHFQ), contrary to what is suggested by the remaining studies. </p> </section> <section id="CD013433-sec-0066"> <h6 class="title">Comparison 2: stem cell therapy versus granulocyte‐colony stimulating factor</h6> <p>One four‐arm study comparing SCT versus G‐CSF assessed quality of life (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>). We used the data from 'peripheral G‐CSF' as the control group, and analysed KCCQ clinical summary score at one year (mean change difference). Small sample size lacked power to detect any difference between groups (SCT plus G‐CSF versus peripheral G‐CSF: MD 4.61 points, 95% CI −5.62 to 14.83; studies = 1, participants = 22). Other additional measures of quality of life used in this study (EQ5D Index score and visual analogue scale, and KCCQ Overall Summary) also found no differences between groups. Therefore, SCT may not improve health‐related quality of life in these participants. </p> </section> <section id="CD013433-sec-0067"> <h6 class="title">Comparison 3: different types or delivery modalities of stem cell therapies against each other </h6> <p>In <a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>, the MLHFQ improved in both SCT groups over 12 months (allogeneic mesenchymal group: P = 0.0022; autologous mesenchymal group: P = 0.1719). The data were shown in figure form only, but there were no differences between the groups. According to the authors, the improvement observed with either form of SCT was "clinically meaningful." </p> </section> </section> <section id="CD013433-sec-0068"> <h5 class="title">Performance status – functional class (NYHA)</h5> <p>Seven studies assessed the change in functional class (NYHA) from baseline. However, the diverse way the outcome was reported precluded pooling of data in a meta‐analysis. For this reason, we presented this outcome narratively. </p> <section id="CD013433-sec-0069"> <h6 class="title">Comparison 1: stem cell therapy versus control (no intervention or sham)</h6> <p><a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> reported the percentage of participants who showed an improvement in their NYHA classification from baseline. The percentage of participants who showed improvement in their NYHA classification at three months and one year was significantly higher in the SCT group (intracoronary BMCs) (P = 0.02). At one year, eight (66.7%) participants showed improvement in NYHA class with no participants demonstrating a deterioration in the SCT group versus one participant (8.3%) in the control group (peripheral placebo) showing improvement with three participants (23.1%) who worsened (P &lt; 0.05). </p> <p><a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a> defined the outcome as the proportion of participants who achieved a NYHA class I/II at the end of the study. While there was a significant improvement in NYHA functional class with treatment with SCT (ixmyelocel‐T) compared to the control group in the ischaemic population (P &lt; 0.05), this was not the case for the non‐ischaemic population (65% with SCT vs 41% with control, reported as "statistically non‐significant<i>"</i>; data presented only in a figure). </p> <p><a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a> assessed changes in NYHA functional class but provided no raw data. The author declared: "Change in NYHA functional class differed significantly between groups at 6 (P = 0.003) but not at 12 months (P = 0.422)." </p> <p><a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a> assessed changes in NYHA class and concluded: "Functional class, evaluated using NYHA classification, showed (…) a statistically significant improvement in the BMMC group, no change in the control group. However, there were no statistically significant differences between groups." </p> <p>The way <a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a> reported change in NYHA functional class is confusing as we could not determine how many participants in each group improved at the end of the study. In the SCT group, after three years, the percentage of participants in NYHA class III and IV had decreased, and 63.4% were in class I or II. In the control group, no participant reached a NYHA class I, and the percentage that was in class II had decreased (at baseline, around a third of all participants within this group was in this category, but none in the SCT group). The authors concluded that there was a significant improvement in functional status on long‐term follow‐up in the SCT group, being the greater effect for participants with class III compared to class IV. </p> <p><a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a> assessed change in NYHA functional class at 12 months. In comparison with control, NYHA class improved significantly in the BMSC group at 12‐month follow‐up (P = 0.050), but not in the BMMC group. </p> <p>In summary, data suggest that SCT may slightly improve NYHA functional class, but the magnitude of this effect is unclear. </p> </section> <section id="CD013433-sec-0070"> <h6 class="title">Comparison 2: stem cell therapy versus granulocyte‐colony stimulating factor</h6> <p>No study assessed change in functional class (NYHA).</p> </section> <section id="CD013433-sec-0071"> <h6 class="title">Comparison 3: different types or delivery modalities of stem cell therapies against each other </h6> <p>In <a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>, at 12 months, the use of allogeneic mesenchymal stem cell was associated with a 66.7% improvement in NYHA functional class versus 27.3% for autologous mesenchymal stem cell (P = 0.0527). </p> </section> </section> <section id="CD013433-sec-0072"> <h5 class="title">Performance status – exercise tolerance – (6‐minute walk test)</h5> <section id="CD013433-sec-0073"> <h6 class="title">Comparison 1: stem cell therapy versus control (no intervention or sham)</h6> <p>Five studies reported exercise tolerance. Due to the variable way the data were originally presented, we combined different measures of effect in the meta‐analysis has been also variable; in some cases, we used the difference of final means (<a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a>; <a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>), while in others, we used the mean change difference (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>). We obtained raw data for <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a> from a figure using specialized software. </p> <p>The evidence was uncertain about the effect of SCT on exercise capacity as assessed by means of the 6MWT compared to control (no intervention or sham) (MD 70.12 m, 95% CI −5.28 to 145.51; I² = 87%; studies = 5, participants = 230; very low‐certainty evidence; <a href="./references#CD013433-fig-0006" title="">Analysis 1.3</a>). </p> <p>There was substantial heterogeneity across studies mainly due to two studies showing a beneficial effect for SCT at six (<a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>) and 24 months (<a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>). Baseline LVEF (%) in these two trials was greater than 30% as compared with the other three trials where participants were in a worse condition (LVEF 30% or less). </p> <p>In addition, <a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> also assessed exercise capacity by improvement in maximum rate of oxygen consumption (Opera), maximum exercise speed, and exercise time. At one year, there was a significant improvement in peak oxygen uptake (VO<sub>2peak</sub>) with SCT (mean change: 3.2 mL/kg/minute, 95% CI 0.69 to 5.71; P = 0.0179), but not with control (mean change: 0.35 mL/kg/minute, 95% CI −2.28 to 1.58; P = 0.6966). There was also an improvement in maximum exercise speed with SCT (1.28 miles per hour, 95% CI 0.30 to 2.26; P = 0.0164), but not with control (0.28 miles per hour, 95% CI −0.22 to 0.78; P = 0.1292). Exercise time was also increased with SCT (162.3 seconds, 95% CI 43.13 to 281.5; P = 0.0131), but there was a decrease with control (−4.385 seconds, 95% CI −61.08 to 52.31; P = 0.8545). </p> </section> <section id="CD013433-sec-0074"> <h6 class="title">Comparison 2: stem cell therapy versus granulocyte‐colony stimulating factor</h6> <p>Two studies within this category reported exercise tolerance (<a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>; <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>). In both cases, we obtained raw data from a figure using specialized software. </p> <p>SCT may improve exercise capacity as assessed by the 6MWT compared to control (G‐CSF) (MD 140.14 m, 95% CI 119.51 to 160.77; I² = 0%; studies = 2, participants = 155; low‐certainty evidence; <a href="./references#CD013433-fig-0012" title="">Analysis 2.3</a>). </p> <p>In <a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>, in participants who received SCT, there was an improvement in exercise capacity measured by an improvement in VO<sub>2peak</sub>, maximum exercise speed, and exercise time. In neither of the two control groups that received only G‐CSF (peripheral G‐CSF and sham SCT plus G‐CSF) was there a favourable effect. The study authors judged these effects on exercise capacity as clinically meaningful. </p> </section> <section id="CD013433-sec-0075"> <h6 class="title">Comparison 3: different types or delivery modalities of stem cell therapies against each other </h6> <p>At 12 months, <a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a> found that 6MWT distance increased in participants receiving allogeneic mesenchymal cells by 37.0 m (95% CI 2.0 to 72.0; P = 0.04) compared with baseline, but did not significantly change in the autologous mesenchymal cells group (7.3 m, 95% CI 47.8 to 33.3; P = 0.71). The between‐group difference was 46.5 m (95% CI 5.5 to 98.5; P = 0.077) at 12 months. </p> <p><a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a> found that 6MWT distance significantly increased at six months in participants assigned to the transendocardial SCT group compared to those in the intracoronary SCT group (mean change difference: 125 m (±33) in the transendocardial group versus 86 m (±13) in the intracoronary group; P = 0.03). </p> <p><a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a> observed no intergroup differences in change in 6MWT after one year between repetitive cell therapy versus single cell therapy (mean increased from 320 m (±92) to 434 m (±71) with repetitive SCT versus 341 m (±87) to 445 m (±96) with single dose SCT; P = 0.65). From baseline to six months, both groups LVEF improved (6.9% (±3.3) in repetitive SCT group; P =0.001; and 7.1% (±3.5) in single‐dose SCT; P = 0.001), but there were no changes between six months and one year. </p> </section> </section> <section id="CD013433-sec-0076"> <h5 class="title">Rehospitalizations</h5> <p><a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a> and <a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> assessed CHF exacerbations requiring hospitalization (e.g. acute heart failure), as part of the composite endpoint MACE. </p> <p><a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a> assessed heart failure exacerbation requiring hospitalization as part of the composite SAE. There were no specific data for this component. </p> <p>In <a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>, the 12‐month all‐cause rehospitalization rate was lower in the allogeneic mesenchymal cell group versus the autologous mesenchymal cell group (28.2% with allogeneic mesenchymal cell versus 70.0% with autologous mesenchymal cell; P = 0.0447). </p> </section> <section id="CD013433-sec-0077"> <h5 class="title">Heart failure</h5> <p>No study assessed heart failure (instead, see 'Change in functional class (NYHA)' above). </p> </section> <section id="CD013433-sec-0078"> <h5 class="title">Ventricular arrhythmia</h5> <section id="CD013433-sec-0079"> <h6 class="title">Comparison 1: stem cell therapy versus control (no intervention or sham)</h6> <p><a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a> assessed sustained ventricular arrhythmia as a component of the composite MACE. The study reported two events in the SCT group (one in the non‐ischaemic population) that were related with the surgical procedure. </p> <p><a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> reported that no cases of ventricular arrhythmia occurred in participants receiving SCT. </p> <p><a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a> found no increase in life‐threatening arrhythmias (no raw data provided). </p> <p><a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a> stated that 3/7 (35%) deaths observed in participants who received SCT were due to documented ventricular arrhythmia or sudden death. </p> <p><a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a> performed continuous ambulatory electrocardiograph (ECG) monitoring. There were no differences between SCT and control group at six months. No raw data of number of events were provided. </p> <p>In <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>, there were no differences in the 24‐hour ambulatory ECG monitoring between SCT and the control group. No raw data of number of events were provided. </p> <p><a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a> assessed new‐onset ventricular arrhythmia as a component of procedural complications and as a component of MACE. No specific data were provided. </p> <p><a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a> investigated the impact of transplanted cells on ventricular electrophysiology with high‐resolution ECG. The study found no effects of transplanted stem cells on QTc interval and QT interval variability, suggesting an absence of proarrhythmic effects of intracoronary BMC transplantation in people with DCM. </p> </section> <section id="CD013433-sec-0080"> <h6 class="title">Comparison 2: stem cell therapy versus granulocyte‐colony stimulating factor</h6> <p>No study assessed ventricular arrhythmia.</p> </section> <section id="CD013433-sec-0081"> <h6 class="title">Comparison 3: different types or delivery modalities of stem cell therapies against each other </h6> <p><a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a> reported three events of sustained ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation) among the 60 participants who received SCT. </p> </section> </section> <section id="CD013433-sec-0082"> <h5 class="title">Complete atrioventricular block</h5> <p>No study assessed complete atrioventricular block.</p> </section> <section id="CD013433-sec-0083"> <h5 class="title">Major adverse cardiovascular events</h5> <p>None of the included studies assessed this composite outcome as defined in our protocol (<a href="./references#CD013433-bbs2-0105" title="Diaz-NavarroR , UrrútiaG , ClelandJG , PoloniD , VillagranF , BangdiwalaS , et al. Stem cell therapy for dilated cardiomyopathy. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD013433. [DOI: 10.1002/14651858.CD013433]">Diaz‐Navarro 2019</a>). For this reason, these results are not presented in our summary of findings tables. However, four studies reported MACE with a different definition. </p> <section id="CD013433-sec-0084"> <h6 class="title">Comparison 1: stem cell therapy versus control (no intervention or sham)</h6> <p>In <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>, MACE included cardiac death, cardiac arrest, myocardial infarction, sustained ventricular arrhythmia (e.g. ventricular tachycardia or ventricular fibrillation), pulmonary oedema, heart failure exacerbation requiring hospitalization (e.g. acute heart failure), unstable angina, or major bleeding (defined as the need for 2 units of blood or greater within one week of the injection procedure or the need for operation because of bleeding). In this study, each participant was counted only once, regardless of the number of events experienced. In the SCT group, 8/18 (44.4%) participants presented an event versus 3/11 (27.3%) participants in the control group. All but one event in participants with non‐ischaemic DCM were due to CHF exacerbation. </p> <p><a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> defined MACE as all‐cause death, myocardial infarction, hospitalization for heart failure, or major arrhythmias. There were two reports of MACE in the SCT group (intracoronary BMCs) and one report in the control group (peripheral placebo) at one year. The two events observed in the SCT group consisted of two deaths due to a non‐cardiac surgical procedure complication and bronchopneumonia. The event in the control group consisted of one arrhythmia.  </p> <p>In <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>, MACE consisted of procedural complications, any new‐onset arrhythmia, haemodynamic instability, and death by any cause. In the SCT group, 11/31 (35.5%) participants presented an event versus 7/17 (41.2%) participants in the control group. It was not clear from the paper if this study counted number of events or number of participants with an event. The events reported in the SCT group were haemodynamic instability (three), atrial fibrillation (three), right or left bundle branch block (four), and ventricular tachycardia (one). The events in the control group consisted of death (two), right bundle branch block (two), left bundle branch block (one), atrial fibrillation (one), and hemodynamic instability (one). </p> </section> <section id="CD013433-sec-0085"> <h6 class="title">Comparison 2: stem cell therapy versus granulocyte‐colony stimulating factor</h6> <p>No study assessed MACE.</p> </section> <section id="CD013433-sec-0086"> <h6 class="title">Comparison 3: different types or delivery modalities of stem cell therapies against each other </h6> <p>In <a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>, MACE rate over 12 months was lower in the allogeneic mesenchymal group (20.3%, 95% CI 6.8% to 52.1%) compared with 57.1% (95% CI: 34.9% to 81.2%) in the autologous mesenchymal group (P = 0.0186). </p> </section> </section> <section id="CD013433-sec-0087"> <h5 class="title">Change in left ventricular ejection fraction</h5> <p>LVEF was the most commonly reported outcome by the studies included in the review.</p> <section id="CD013433-sec-0088"> <h6 class="title">Comparison 1: stem cell therapy versus control (no intervention or sham)</h6> <p>Eight studies comparing SCT versus control (no intervention or sham) reported changes in LVEF. Due to the variable way the data were originally presented, the measure of the effect we combined in the meta‐analysis was also variable; in some cases we used the difference of final means (<a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a>; <a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>; <a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a>; <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>; <a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>), while in others we used the mean change difference (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>). We obtained raw data for <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a> from a figure using specialized software. </p> <p>SCT did not improve LVEF in participants with DCM compared to control (no intervention or sham) (MD 5.41%, 95% CI −2.29 to 13.10; I² = 94%; studies = 8, participants = 353; <a href="./references#CD013433-fig-0007" title="">Analysis 1.4</a>). There was substantial heterogeneity across studies, that was due mainly to <a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a>, where participants in the SCT group surprisingly reached a final mean value that doubled the baseline value, and, to a lesser extent, <a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>. </p> </section> <section id="CD013433-sec-0089"> <h6 class="title">Comparison 2: stem cell therapy versus granulocyte‐colony stimulating factor</h6> <p>Three studies comparing STC versus G‐CSF reported changes in LVEF. For one study, we used difference in final means (<a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>), while in the two other studies, we used mean change difference (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>). In addition, we obtained raw data for <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a> and <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a> from a figure using specialized software. </p> <p>SCT may improve LVEF in participants with DCM (MD 6.61%, 95% CI 5.61 to 7.62; I² = 0%; studies = 3; participants = 182; <a href="./references#CD013433-fig-0013" title="">Analysis 2.4</a>). </p> </section> <section id="CD013433-sec-0090"> <h6 class="title">Comparison 3: different types or delivery modalities of stem cell therapies against each other </h6> <p><a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a> found LVEF increased in participants receiving allogeneic mesenchymal cells by 8.0% (P = 0.004) compared with 5.4% in the autologous mesenchymal cells group at 12 months (P = 0.116) (allogeneic versus autologous group: between‐group P = 0.4887). This resulted in the LVEF rising above 40% in 46.7% of participants receiving allogeneic mesenchymal cells versus 22.2% of participants receiving autologous mesenchymal cells. </p> <p><a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a> found LVEF increased in both groups; however, the change at six months was significantly higher in the transendocardial SCT group than in the intracoronary SCT group. According to the authors, the intracoronary group principally improved their LVEF within the first month, whereas in the transendocardial group the main improvement occurred between months one and three. Authors also note that "LVEF improvement correlated significantly with the percent of cells retained in the myocardium 18 hours after intracoronary or trans endocardial delivery (r=0.53, P &lt; 0.001)." </p> <p><a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a> observed no intergroup differences in change in LVEF after one year between repetitive cell therapy versus single cell therapy (mean increased from 32.2% (±9.3) to 41.2% (±6.5) with repetitive cell therapy, and from 30.0% (±7.0) to 37.9% (±5.3) with single cell therapy; P = 0.40). </p> </section> </section> <section id="CD013433-sec-0091"> <h5 class="title">Change in left ventricular end‐systolic volume</h5> <section id="CD013433-sec-0092"> <h6 class="title">Comparison 1: stem cell therapy versus control (no intervention or sham)</h6> <p>Four studies comparing SCT versus control (no intervention or sham) reported changes in LVESV. We used difference in final means in two studies (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>), while in two other cases, we used mean change difference (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>). We obtained raw data for <a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a> from a figure using specialized software. </p> <p>The combined meta‐analysis of these studies found a greater reduction in the LVESV between participants who received SCT and those who had not (MD −30.97 mL, 95% CI −54.18 to −7.75; I² = 0%; studies = 4, participants = 251; <a href="./references#CD013433-fig-0008" title="">Analysis 1.5</a>). However, the evidence was uncertain. </p> </section> <section id="CD013433-sec-0093"> <h6 class="title">Comparison 2: stem cell therapy versus granulocyte‐colony stimulating factor</h6> <p>Only one study comparing SCT versus G‐CSF reported changes in LVESV (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>). There was no evidence of a difference observed with STC plus G‐CSF (intracoronary BMC) compared with peripheral G‐CSF (MD −71.30 mL, 95% CI −150.96 to 8.36; studies = 1, participants = 27; <a href="./references#CD013433-fig-0014" title="">Analysis 2.5</a>). There were no intragroup differences (pre–post) in either group. </p> </section> <section id="CD013433-sec-0094"> <h6 class="title">Comparison 3: different types or delivery modalities of stem cell therapies against each other </h6> <p><a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a> reported data for changes in LVESV as a figure. There was no difference after six months between groups (−18 mL with transendocardial SCT versus −13 mL with intracoronary SCT; P = 0.10). </p> <p><a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a> assessed changes in LVESV but reported no data. </p> </section> </section> <section id="CD013433-sec-0095"> <h5 class="title">Change in left ventricular end‐diastolic volume</h5> <section id="CD013433-sec-0096"> <h6 class="title">Comparison 1: stem cell therapy versus control (no intervention or sham)</h6> <p>Four studies comparing SCT versus control (no intervention or sham) reported changes in LVEDV. We used difference in final means in two studies (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a>), while in two other cases, we used mean change difference (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>; <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>). We obtained raw data for Henry 2014 from a figure using specialized software. </p> <p>The combined meta‐analysis found a greater reduction in the LVEDV between participants who had received SCT than those who had not (MD −23.40 mL, 95% CI −49.74 to 2.94; I² = 0%; studies = 4, participants = 251; <a href="./references#CD013433-fig-0009" title="">Analysis 1.6</a>). However, the evidence was uncertain. </p> </section> <section id="CD013433-sec-0097"> <h6 class="title">Comparison 2: stem cell therapy versus granulocyte‐colony stimulating factor</h6> <p>One study comparing SCT versus G‐CSF reported change in LVEDV (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>). There was no evidence of a difference between STC plus G‐CSF (intracoronary BMC) and peripheral G‐CSF groups (MD −81.10 mL, 95% CI −175.54 to 13.34; studies = 1, participants = 27; <a href="./references#CD013433-fig-0015" title="">Analysis 2.6</a>). There were no intragroup differences (pre–post) between groups. </p> </section> <section id="CD013433-sec-0098"> <h6 class="title">Comparison 3: different types or delivery modalities of stem cell therapies against each other </h6> <p>One study comparing different types or delivery modalities of SCT assessed change in LVEDV; however, there were no data reported (<a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a>). </p> </section> </section> <section id="CD013433-sec-0099"> <h5 class="title">Change in plasma natriuretic peptide levels (BNP and NT‐proBNP)</h5> <section id="CD013433-sec-0100"> <h6 class="title">Comparison 1: stem cell therapy versus control (no intervention or sham)</h6> <p>Four studies comparing SCT versus control (no intervention or sham) assessed BNP or NT‐proBNP levels, but we could not combine data in the meta‐analysis. </p> <p><a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a> measured changes in BNP levels but the paper only provides specific data for the SCT group and for the entire study population (not specifically for the participants with non‐ischaemic DCM). </p> <p><a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a> measured changes in BNP concentrations, but provided no raw data. The authors stated: "Change in BNP concentrations did not differ significantly between the groups (P = 0.146 and 0.241 at 6 and 12 months, respectively)." </p> <p><a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> measured changes in N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) plasma levels and found decreased levels in participants who received SCT at one year (intragroup mean change difference −136.0 pg/mL, 95% CI −519.6 to 247.6; P = 0.0023), but not in those who had not (peripheral placebo) (−175.5 pg/mL, 95% CI −493.2 to 147.1; P = 0.2218). There was no P value for the between‐groups comparison provided. </p> <p><a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a> measured changes in plasma BNP levels and found a difference in final means between participants who had received SCT and those who had not (MD [final means] −124.20 ng/L, 95% CI −223.37 to −25.03). </p> </section> <section id="CD013433-sec-0101"> <h6 class="title">Comparison 2: stem cell therapy versus granulocyte‐colony stimulating factor</h6> <p>Three studies comparing SCT versus G‐CSF reported NT‐proBNP levels that could be pooled in a meta‐analysis. We used difference in final means in one study (<a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>), while in two other studies, we used mean change difference (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>; <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>). We obtained raw data for <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a> and <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>) from a figure using specialized software. </p> <p>The meta‐analysis showed a greater reduction of NT‐proBNP levels with cell therapy (MD −1632.09 pg/mL, 95% CI −2180.18 to −1083.99; I² = 91%; studies = 3, participants = 181; <a href="./references#CD013433-fig-0016" title="">Analysis 2.7</a>). However, the evidence was uncertain. There was substantial heterogeneity across studies, which was due mainly to <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>. </p> </section> <section id="CD013433-sec-0102"> <h6 class="title">Comparison 3: different types or delivery modalities of stem cell therapies against each other </h6> <p>Two studies comparing different types or delivery modalities of SCT assessed NT‐proBNP levels. </p> <p>In <a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a>, NT‐proBNP levels declined in both groups after six months; this was more in the transendocardial SCT group than in the intracoronary SCT group (−628 pg/mL with transendocardial SCT versus −315 pg/mL with intracoronary SCT; P = 0.04). </p> <p>In <a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a>, there were no intergroup differences in change in NT‐proBNP levels between repetitive cell therapy and single cell therapy (mean increased from 1525 pg/mL (±1030) to 732 pg/mL (±725) with repetitive cell therapy, and from 1753 pg/mL (±1008) to 1087 pg/mL (±978) with single cell therapy; P = 0.33). From baseline to six months, both groups displayed a significant improvement in decrease in NT‐proBNP, with no additional changes between six months and one year in either group. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013433-sec-0103" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013433-sec-0103"></div> <p>DCM is the most common form of non‐ischaemic cardiomyopathy worldwide (<a href="./references#CD013433-bbs2-0070" title="JefferiesJL , TowbinJA . Dilated cardiomyopathy. Lancet2010;375(9716):752-62.">Jefferies 2010</a>; <a href="./references#CD013433-bbs2-0076" title="McKennaWJ , MaronBJ , ThieneG . Classification, epidemiology, and global burden of cardiomyopathies. Circulation Research2017;121:722-30.">McKenna 2017</a>) and represents one of the leading causes of heart failure requiring heart transplantation in adults (<a href="./references#CD013433-bbs2-0081" title="MerloM , CannatáA , VitaglianoA , ZambonE , LardieriG , SinagraG . Clinical management of dilated cardiomyopathy: current knowledge and future perspectives. Expert Review of Cardiovascular Therapy2016;14(2):137-40.">Merlo 2016</a>; <a href="./references#CD013433-bbs2-0093" title="StehlikJ , EdwardsLB , KucheryavayaAY , BendenC , ChristieJD , DobbelsF , et al. The registry of the International Society of Heart and Lung Transplantation: twenty-eight adult heart transplantation report. Journal of Heart and Lung Transplantation2011;30(10):1078-94.">Stehlik 2011</a>). Since the early 1990s, optimal medical management for heart failure according to evidence‐based guidelines has improved the long‐term prognosis in people with DCM (<a href="./references#CD013433-bbs2-0079" title="MerloM , PivettaA , PinamontiB , StolfoD , ZecchinM , BarbatiG , et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. European Journal of Heart Failure2014;16(3):317-24.">Merlo 2014</a>; <a href="./references#CD013433-bbs2-0085" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37:2129-200.">Ponikowski 2016</a>; <a href="./references#CD013433-bbs2-0104" title="YancyC , JessupM , BozkurtB , ButlerJ , CaseyD , DraznerM , et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2013;128(16):e240-27.">Yancy 2013</a>). Nevertheless, some patients experience a trend towards worsening of their left ventricular function (<a href="./references#CD013433-bbs2-0080" title="MerloM , StolfoD , AnziniM , NegriF , PinamontiB , BarbatiG , et al. Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist?Journal of the American Heart Association2015;4(1):e001504.">Merlo 2015</a>), and most require continuous intravenous inotropic therapy, ventricular assist devices, and mechanical ventilation while awaiting a heart transplant (<a href="./references#CD013433-bbs2-0070" title="JefferiesJL , TowbinJA . Dilated cardiomyopathy. Lancet2010;375(9716):752-62.">Jefferies 2010</a>). </p> <p>SCT has been proposed as a possible alternative therapy for DCM, after some studies suggested a favourable effect on functional status and mortality (<a href="./references#CD013433-bbs2-0060" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34+ cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72.">Frljak 2018</a>; <a href="./references#CD013433-bbs2-0084" title="PoglajenG , ZemljičG , FrljakS , CerarA , AndročecV , SeverM , et al. Stem cell therapy in patients with chronic nonischemic heart failure. Stem Cells International2018;2018:6487812.">Poglagen 2018</a>). Although SCT has been reported to be safe (<a href="./references#CD013433-bbs2-0078" title="MenaschéP . Cell therapy trials for heart regeneration-lessons learned and future directions. Nature Reviews. Cardiology2018;15(11):659-71.">Menasché 2018</a>), its efficacy in people with DCM is still controversial, and SCT is not included in the recommendations of the main clinical practice guidelines for heart failure (<a href="./references#CD013433-bbs2-0085" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37:2129-200.">Ponikowski 2016</a>; <a href="./references#CD013433-bbs2-0104" title="YancyC , JessupM , BozkurtB , ButlerJ , CaseyD , DraznerM , et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2013;128(16):e240-27.">Yancy 2013</a>). We reviewed the available information on the safety and efficacy of SCT administered to people with DCM and heart failure, based on RCTs. </p> <section id="CD013433-sec-0104"> <h3 class="title" id="CD013433-sec-0104">Summary of main results</h3> <p>The review included 13 RCTs. Eight studies compared the effect of SCT with usual care or sham treatment; three studies compared the administration of stem cells after cell mobilization with G‐CSF injected subcutaneously with controls receiving subcutaneous G‐CSF but not cells (<a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>; <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>; <a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>); and four studies compared different modes of SCT delivery. Among these, one study compared the administration of autologous mesenchymal cells with allogenic mesenchymal cells delivered transendocardially (<a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a>); one study compared intracoronary and transendocardial delivery of stem cells (<a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a>); one study examined repetitive versus single‐infusion of stem cells (both groups receiving mobilization with G‐CSF) (<a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a>), and one study compared intracoronary administration of bone marrow mononuclear cells versus mesenchymal stem cells (<a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a>). </p> <p>Participants were diagnosed with DCM after elimination of secondary causes of heart failure, and all were given optimal standard pharmacological treatment. Two studies had a six‐month follow‐up, seven reported follow‐up data for 12 months, and four had long‐term follow‐up of more than 12 months. Here, we define as primary outcomes all‐cause mortality, and safety both at the time of stem cell collection and administration, or within 30 days of treatment. </p> <p>Our main findings for SCT compared with usual care or sham treatment (comparison 1) were as follows. </p> <p> <ul id="CD013433-list-0020"> <li> <p>We are uncertain whether SCT reduces all‐cause mortality.</p> </li> <li> <p>We are uncertain whether SCT increases the risk of procedural complications in people with DCM. </p> </li> <li> <p>We are uncertain whether SCT improves health‐related quality of life.</p> </li> <li> <p>We are uncertain whether SCT improves exercise capacity as assessed by the 6MWT.</p> </li> <li> <p>SCT may slightly improve functional class as defined by the New York Association (NHYA).</p> </li> <li> <p>No studies assessed MACE as defined in our protocol (<a href="./references#CD013433-bbs2-0105" title="Diaz-NavarroR , UrrútiaG , ClelandJG , PoloniD , VillagranF , BangdiwalaS , et al. Stem cell therapy for dilated cardiomyopathy. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD013433. [DOI: 10.1002/14651858.CD013433]">Diaz‐Navarro 2019</a>). </p> </li> <li> <p>SCT may not increase the risk of ventricular arrhythmia.</p> </li> </ul> </p> <p>Our main findings for SCT (any type) plus G‐CSF compared with G‐CSF (but no cells) (comparison 2) were as follows. </p> <p> <ul id="CD013433-list-0021"> <li> <p>We are uncertain whether SCT reduces all‐cause mortality.</p> </li> <li> <p>We are uncertain whether SCT increases the risk of procedural complications.</p> </li> <li> <p>SCT may not improve health‐related quality of life.</p> </li> <li> <p>SCT may improve exercise capacity as assessed by the 6MWT.</p> </li> <li> <p>No studies assessed improvement in functional class as defined by NHYA.</p> </li> <li> <p>No studies assessed MACE as defined in our protocol (<a href="./references#CD013433-bbs2-0105" title="Diaz-NavarroR , UrrútiaG , ClelandJG , PoloniD , VillagranF , BangdiwalaS , et al. Stem cell therapy for dilated cardiomyopathy. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD013433. [DOI: 10.1002/14651858.CD013433]">Diaz‐Navarro 2019</a>), or ventricular arrhythmia. </p> </li> </ul> </p> <p>The evidence also suggests some effects of SCT on physiological outcomes such as change in LVEF, LVESV, and LVEDV, and to some extent in laboratory parameters (BNP) presumably related with cardiac function, but clinical implications of these observations remain unclear. </p> <p>These results are somewhat paradoxical because, in comparison 2, the participants in the control group received active treatment (but without cells), that is considered superior to the control used in comparison 1. Consequently, the explanation for these apparently better results must lie in the nature of the experimental group (the specific mode of administration of SCT) or the characteristics of the study population, or both. This potential beneficial effect observed in a limited number of studies of low certainty suggests that the combination of G‐CSF with SCT compared with SCT alone might produce additional benefits. In an experimental model, therapy with G‐CSF has been reported to have a protective effect on people with heart failure following myocardial infarction (<a href="./references#CD013433-bbs2-0063" title="HaradaM , QinY , TakanoH , MinaminoT , ZouY , TokoH , et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nature Medicine2005;11:305-11.">Harada 2005</a>). However, these results must be treated with caution because the study on which they were based had major inconsistencies between the registry entry of the trial and its publication (i.e. different outcomes, interventions, and timing), and hence should be interpreted with caution. </p> <p>There was a wide variation in mortality rates across studies. This variation could be due to large differences in follow‐up, or in baseline participant characteristics, among other factors. In addition, most studies did not describe the cause of death. This makes it difficult to draw meaningful conclusions with regard to the effects of SCT on all‐cause mortality. </p> <p>There were substantial differences between the studies in terms of the characteristics of the study population and the cell therapy used (type and origin of the cells infused, cell dose, route, and cell delivery methods), that would have recommended performing subgroup analysis as was originally planned. However, the limited number of studies in each category prevented this. </p> <p>Some additional studies have compared different cell therapy modalities with each other. Although they did not provide direct evidence of efficacy, they contributed to understanding the effects observed with specific modalities of SCT delivery. Limited and preliminary evidence suggests that repetitive infusions are no better than a single treatment with SCT, and that transendocardial injection is probably better than intracoronary delivery of cells. </p> <p>In summary, this systematic review and meta‐analysis found no clear evidence that SCT is beneficial in terms of reducing all‐cause mortality, and improving health‐related quality of life and performance status in people with DCM. Thus, more research is needed to establish the role of SCT in the treatment of DCM and the most effective treatment modalities. New evidence from several ongoing studies may help determine the role of SCT in clinical practice. </p> </section> <section id="CD013433-sec-0105"> <h3 class="title" id="CD013433-sec-0105">Overall completeness and applicability of evidence</h3> <p>All the studies included in this review were conducted in cohorts of people with DCM. This diagnosis was made once any secondary causes of myocardial disease, including ischaemic heart disease, were excluded. However, some important inclusion criteria, such as LVEF, varied widely between the trials. Some authors considered LVEF less than 50%, while others used less than 45%, 40% or less, less than 35%, or 30% or less, and this may have affected the results. However, these studies remain as a representative population of people with DCM under optimal pharmacological medical treatment that might benefit from SCT. </p> <p>Most included trials evaluated cell therapy versus non‐cell therapy, although there were some important differences in the specific modalities of cell therapy used. Most studies used BMMCs and delivered them via a single intracoronary infusion. </p> <p>Trials included in this meta‐analysis evaluated a broad variety of outcomes and used diverse definitions, which represent a potential limitation of our review that precluded the possibility of evaluating the effects of SCT on clinically relevant outcomes. Beyond mortality, most of the outcomes evaluated were secondary and some were surrogate indices, such as the LVEF, LVEDV, LVESV, and plasma BNP levels. </p> </section> <section id="CD013433-sec-0106"> <h3 class="title" id="CD013433-sec-0106">Quality of the evidence</h3> <p>Overall, the studies included in this review were of a suboptimal quality, which in turn affects our assessment of the certainty of the evidence available from the analyzed results. Only one study qualified as 'low risk of bias' in all domains assessed, after we obtained further information from the study authors (<a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>). It is worth noting that insufficiencies were consistently detected in the quality of the reporting in most studies, whereby aspects key to assessing the risk of bias were not described in sufficient detail. It is important that medical journals that publish therapeutic research studies (RCTs) adhere to international reporting guidelines, such as CONSORT (<a href="./references#CD013433-bbs2-0090" title="SchulzKF , AltmanDG , MoherD . CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c332.">Schulz 2010</a>), so that the practical utility of the information published is increased. Moreover, only some, but not all, of the studies included in this review were registered in a public registry, which precluded us from obtaining complementary data or further verifying the information in this review. It is important that all RCTs are registered as a guarantee of transparency and to provide another source of information beyond any related publication. We wrote to the authors of each trial to gather additional information that might modify our conclusions about the risk of bias and the certainty of evidence. As of June 2021, only one of the 10 authors has responded (<a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>). </p> <p>It is important to consider the variability in the numerical reporting of the results of the RCTs included in this review. In some cases, the format of the data was not useful for a meta‐analysis because of a lack of key details. In some cases, the observed differences between treatments were only supported by a P value, which does not allow their translation into a measure of the effect. In other cases, these data were only reported graphically without the corresponding raw data. The use of specialized software (GetData Graph Digitizer 2.26) allowed us to retrieve the original data from graphs in some studies. In addition, some reported data were incomplete, particularly continuous variables where the mean of the change (final versus basal) and its SD were required. This issue is particularly relevant in this review since the original studies were mostly small trials, and despite randomization there were baseline differences between the groups in most of the variables analyzed. This shortcoming has forced us to combine results in our analysis where effects have been quantified using different methods, which adds uncertainty to the results obtained. In conclusion, we consider the certainty of the evidence in this review to be limited, although this may not affect our overall conclusions. </p> </section> <section id="CD013433-sec-0107"> <h3 class="title" id="CD013433-sec-0107">Potential biases in the review process</h3> <p>This review was based on an exhaustive search for RCTs and their careful selection. During this process, we identified other potentially relevant studies but their design was not adequate for our review. For example, we identified some controlled, but not randomized, studies and their inclusion would have added risk of bias and confusion to our review. </p> </section> <section id="CD013433-sec-0108"> <h3 class="title" id="CD013433-sec-0108">Agreements and disagreements with other studies or reviews</h3> <p>In this systematic review, we focused on the effects of SCT in people with DCM based on the main outcomes of mortality and complications of the procedures, as well as other surrogate variables of secondary interest. While some earlier systematic reviews informed this approach, they are fundamentally different from our review (<a href="./references#CD013433-bbs2-0071" title="JiaoR , LiuY , YangWJ , ZhuXY , LiJ , TangQZ . Effects of stem cell therapy on dilated cardiomyopathy. Saudi Medical Journal2014;35(12):1463-8.">Jiao 2014</a>; <a href="./references#CD013433-bbs2-0074" title="LuY , WangY , LinM , ZhouJ , WangZ , JiangM , et al. A systematic review of randomised controlled trials examining the therapeutic effects of adult bone marrow-derived stem cells for non-ischaemic dilated cardiomyopathy. Stem Cell Research &amp; Therapy2016;7(1):186.">Lu 2016</a>; <a href="./references#CD013433-bbs2-0075" title="Marquis-GravelG , StevensLM , ManosurS , AvramR , NoiseuxN . Stem cell therapy for the treatment of nonischemic cardiomyopathy: a systematic review of the literature and meta-analysis of randomized controlled trials. Canadian Journal of Cardiology2014;30(11):1378-84.">Marquis‐Gravel 2014</a>; <a href="./references#CD013433-bbs2-0089" title="RongSL , WangZK , ZhouXD , WangXL , YangZM , LiB . Efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy: a systematic appraisal and meta-analysis. Journal of Translational Medicine2019;17(1):221.">Rong 2019</a>; <a href="./references#CD013433-bbs2-0101" title="WenY , DingJ , ZhangB , GaoQ . Bone marrow-derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy. A meta-analysis. European Journal of Clinical Investigation2018;48(4):e12894.">Wen 2018</a>). It should be noted that none has a previous protocol record. Only one (<a href="./references#CD013433-bbs2-0089" title="RongSL , WangZK , ZhouXD , WangXL , YangZM , LiB . Efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy: a systematic appraisal and meta-analysis. Journal of Translational Medicine2019;17(1):221.">Rong 2019</a>) addressed the assessment of risk of bias by strictly adopting the methodology proposed by Cochrane (<a href="./references#CD013433-bbs2-0068" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from  training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). In general, the evaluation of the risk of bias or of the quality of the studies carried out in these reviews is very lenient, considering as adequate the simple fact of stating (although without giving details to verify them) some key characteristics of the study design. However, none of these reviews integrated quality assessment into the interpretation of their results. </p> <p>Our conclusions about mortality were consistent with those of some previous systematic reviews (<a href="./references#CD013433-bbs2-0089" title="RongSL , WangZK , ZhouXD , WangXL , YangZM , LiB . Efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy: a systematic appraisal and meta-analysis. Journal of Translational Medicine2019;17(1):221.">Rong 2019</a>; <a href="./references#CD013433-bbs2-0101" title="WenY , DingJ , ZhangB , GaoQ . Bone marrow-derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy. A meta-analysis. European Journal of Clinical Investigation2018;48(4):e12894.">Wen 2018</a>), but disagree with those expressed by others (<a href="./references#CD013433-bbs2-0071" title="JiaoR , LiuY , YangWJ , ZhuXY , LiJ , TangQZ . Effects of stem cell therapy on dilated cardiomyopathy. Saudi Medical Journal2014;35(12):1463-8.">Jiao 2014</a>; <a href="./references#CD013433-bbs2-0074" title="LuY , WangY , LinM , ZhouJ , WangZ , JiangM , et al. A systematic review of randomised controlled trials examining the therapeutic effects of adult bone marrow-derived stem cells for non-ischaemic dilated cardiomyopathy. Stem Cell Research &amp; Therapy2016;7(1):186.">Lu 2016</a>). All of these reviews, in addition to using eligibility criteria differing from ours (in some cases they included observational studies), did not consider the separate analysis of studies where mobilization with cytokines was used in the control group. This means that, when all the studies in the same pool are combined, the results are more favourable to SCT given the influence that the studies of <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a> and <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a> had on the overall results. As previously noted, we consider that these studies deserve separate consideration given their specific characteristics regarding the modality of administration of cell therapy. Otherwise, analysing them with the rest of the studies will lead to inappropriate conclusions about the benefits of SCT in this pathology as observed by these reviews, which we believe are not supported by the available data. </p> <p>A similar situation occurs when observing the effect of SCT on the surrogate variables of secondary interest that are based on cardiac volumes. All the aforementioned non‐Cochrane reviews support an increase in LVEF after SCT therapy but none of them reported an increase of 5%, a value associated with a reduction in mortality in the follow‐up of people with heart failure with reduced ejection fraction (<a href="./references#CD013433-bbs2-0054" title="DunlaySM , RogerVL , WestonSA , JiangR , RedfieldMM . Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circulation Heart Failure2012;5(6):720-6.">Dunlay 2012</a>). This is consistent with a study in which, through a sequential analysis based on two Cochrane systematic reviews where SCT was used as therapy in acute myocardial infarction and heart failure, there was no clinically relevant difference in LVEF observed after treatment (<a href="./references#CD013433-bbs2-0059" title="FisherSA , DoreeC , TaggartDP , MathurA , Martin-RendonE . Cell therapy for heart disease: trial sequential analyses of two Cochrane reviews. Clinical Pharmacology and Therapeutics2016;100(1):88-101.">Fisher 2016b</a>). </p> <p>Other Cochrane Reviews addressing mortality reduction and the adverse effects of SCT in people with heart failure secondary to ischaemic cardiomyopathy support the possibility of success (<a href="./references#CD013433-bbs2-0057" title="FisherSA , ZhangH , DoreeC , MathurA , Martin-RendonE . Stem cell treatment for acute myocardial infarction. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD006536. [DOI: 10.1002/14651858.CD006536.pub4]">Fisher 2015</a>; <a href="./references#CD013433-bbs2-0058" title="FisherSA , DoreeC , MathurA , TaggartDP , Martin-RendonE . Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database of Systematic Reviews2016, Issue 12. Art. No: CD007888. [DOI: 10.1002/14651858.CD007888.pub3]">Fisher 2016a</a>). This suggests that the treatment in question could provide greater benefit to this group of patients. Nonetheless, no studies to date have shown that people with ischaemic heart failure have better response to cell therapy compared to people with DCM. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013433-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013433-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013433-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013433-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention), Outcome 1: All‐cause mortality" data-id="CD013433-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention), Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention), Outcome 2: Health‐related quality of life" data-id="CD013433-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention), Outcome 2: Health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention), Outcome 3: Performance status – 6‐minute walk test (m)" data-id="CD013433-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention), Outcome 3: Performance status – 6‐minute walk test (m) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention), Outcome 4: Change in left ventricular ejection fraction" data-id="CD013433-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention), Outcome 4: Change in left ventricular ejection fraction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention), Outcome 5: Change in left ventricular end‐systolic volume" data-id="CD013433-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention), Outcome 5: Change in left ventricular end‐systolic volume </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention), Outcome 6: Change in left ventricular end‐diastolic volume" data-id="CD013433-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention), Outcome 6: Change in left ventricular end‐diastolic volume </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 1: All‐cause mortality" data-id="CD013433-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 2: Health‐related quality of life" data-id="CD013433-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 2: Health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 3: Performance status – 6‐minute walk test (m)" data-id="CD013433-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 3: Performance status – 6‐minute walk test (m) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 4: Change in left ventricular ejection volume" data-id="CD013433-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 4: Change in left ventricular ejection volume </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 5: Change in left ventricular end‐systolic volume" data-id="CD013433-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 5: Change in left ventricular end‐systolic volume </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 6: Change in left ventricular end‐diastolic volume" data-id="CD013433-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 6: Change in left ventricular end‐diastolic volume </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013433-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/urn:x-wiley:14651858:media:CD013433:CD013433-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 7: Change in plasma natriuretic peptide levels (BNP and NT‐proBNP)" data-id="CD013433-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_t/tCD013433-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF), Outcome 7: Change in plasma natriuretic peptide levels (BNP and NT‐proBNP) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/media/CDSR/CD013433/image_n/nCD013433-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013433-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Stem cell therapy compared to control for dilated cardiomyopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>SCT compared to control for DCM</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> DCM (non‐ischaemic)<br/><b>Setting:</b> hospital for procedure; follow‐up ambulatory<br/><b>Intervention:</b> SCT (any type)<br/><b>Comparison:</b> Control (no intervention or sham intervention) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with SCT</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Mean follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>361<br/>(7 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b><br/>(0.54 to 1.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>165 per 1000</b> </p> <p>(106 to 257)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether SCT reduces all‐cause mortality in people with DCM.</p> <p>We excluded 1 further study (29 participants) from the meta‐analysis because there were no events in either group (<a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a>). </p> <p>See <a href="./full#CD013433-tbl-0002">Table 1</a> for more details on mortality. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Procedural complications</b> </p> <p>Within 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>361</p> <p>(7 studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether SCT increases the risk of procedural complications in people with DCM. </p> <p>The definition of this outcome varied widely between studies. In some, it was included as an adverse event. For this reason, this outcome is only presented narratively. Overall, SCT is perceived as a safe intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Mean follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>272<br/>(5 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>d,e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD 0.62 higher</b> </p> <p>(0.01 higher to 1.23 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether SCT improves health‐related quality of life in people with DCM. </p> <p>It was not possible to calculate mean value in the control group, considering that studies used different scales. Using <a href="./references#CD013433-bbs2-0048" title="CohenJ . Statistical Power Analysis in the Behavioural Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc, 1988.">Cohen 1988</a>'s approach, we interpret this SMD as a medium‐to‐large effect estimate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Performance status – 6MWT (m)</b> </p> <p>Mean follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230<br/>(5 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b> </p> <p><sup>a,b,e,</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246.9 (SD 141.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 70.12 m higher</b> </p> <p>(5.28 lower to 145.51 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether SCT improves performance status assessed by 6MWT in people with DCM. </p> <p>For the risk with control we used the mean average of the control groups of the included studies. </p> <p>1 additional study assessed exercise time and found an improvement with SCT (P = 0.01) but a decrease in the control group after 1 year (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Performance status – change in functional class (NYHA)</b> </p> <p>Mean follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>398</p> <p>(6 studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SCT may result in a slight functional class (NYHA) improvement in people with DCM.</p> <p>6 studies reported change in functional class (NYHA) in a diverse way that did not allow pooling of data. All studies reported a significant improvement with SCT. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MACE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies reported MACE as defined in our protocol (<a href="./references#CD013433-bbs2-0105" title="Diaz-NavarroR , UrrútiaG , ClelandJG , PoloniD , VillagranF , BangdiwalaS , et al. Stem cell therapy for dilated cardiomyopathy. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD013433. [DOI: 10.1002/14651858.CD013433]">Diaz‐Navarro 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular arrhythmia</b> </p> <p>Mean follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>504</p> <p>(8 studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SCT may not increase the risk of ventricular arrhythmia in people with DCM.</p> <p>Overall, ventricular arrhythmia rates were similar between groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>6MWT:</b> 6‐minute walk test; <b>CI:</b> confidence interval; <b>DCM:</b> dilated cardiomyopathy; <b>MACE:</b> major adverse cardiovascular events; <b>MD:</b> mean difference; <b>NYHA:</b> New York Heart Association; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SCT:</b> stem cell therapy; <b>SD:</b> standard deviation; <b>SMD:</b> standardized mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to unclear risk of bias related to randomization and allocation concealment and high risk of attrition bias and selective reporting.<br/><sup>b</sup>Downgraded two levels for imprecision due to optimal information size not being met and confidence intervals including the threshold of null effect.<br/><sup>c</sup>Downgraded two levels for inconsistency as the outcome had high heterogeneity within included studies.<br/><sup>d</sup>Downgraded one level due to unclear risk of bias related to randomization and allocation, and high risk of bias regarding blinding.<br/><sup>e</sup>Downgraded two levels due to inconsistency (I² = 80%). The substantial heterogeneity observed was attributable to <a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a>, a robust trial with a relatively large sample size, which did not show a beneficial effect of SCT on this outcome (measured using the Minnesota Living with Heart Failure Questionnaire), contrary to what is suggested by the other studies.<br/><sup>f</sup>Downgraded one level for imprecision due to wide confidence intervals (reflecting both a null and a relevant effect).<br/><sup>g</sup>Downgraded one level for indirectness due to different definitions of the outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Stem cell therapy compared to control for dilated cardiomyopathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013433-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of mortality rates</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study (arm)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Follow‐up</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>SCT</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>No SCT</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a><b> </b>(autologous) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a><b> </b>(allogeneic) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0004" title="MartinoH , BrofmanP , GrecoO , BuenoR , BodaneseL , ClausellN , et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). European Heart Journal2015;36(42):2898-904. TuraBR , MartinoHF , GowdakLH , dos SantosRR , DohmannHF , KriegerJE , et al. Multicenter randomized trial of cell therapy in cardiopathies MiHeart study. Trials2007;8:2. ">Martino 2015 (MiHEART)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0006" title="SethS , BhargavaB , NarangR , MohantyS , RayR , GulatiG , et al. A randomised trial of Autologous Bone marrow Cells in Dilated cardiomyopathy (ABCD). European Heart Journal2009;30:501. SethS , BhargavaB , NarangR , RayR , MohantyS , GulatiG , et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. Journal of the American College of Cardiology2010;55(15):1643-4. SethS , NarangR , BhargavaB , RayR , MohantyS , GulatiG , et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. Journal of the American College of Cardiology2006;48(11):2350-1. ">Seth 2010 (ABCD)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 12 m (3 yr)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 12 m (5 yr)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a> (IC) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a> (TE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a> (repetitive) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a><b> </b>(single) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0011" title="WangJA , XieXJ , HeH , SunY , JiangJ , LuoRH , et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih2006;34(2):107-10. ">Wang 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0012" title="WuZH , YuanMY , LiHM , QiuJJ , LaoHZ , WuXY , et al. Autologous peripheral blood stem cells transplantation for the treatment of dilated cardiomyopathy: a 24-month follow-up in 38 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2010;14(1):121-25. [DOI: dx.doi.org/10.3969/j.issn.1673-8225.2010.01.026]">Wu 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 12  m (18 m)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Up to 12 m</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>&gt; 12 m</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35/113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TOTAL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48/432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59/256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.0%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>IC: intracoronary; m: month; SCT: stem cell therapy; TE: transendocardial; yr: year.</p> <p><sup>a</sup><a href="./references#CD013433-bbs2-0003" title="BrucknerBA , GhodsizadA , HammanBL , BullDA , LattoufOM , SmediraNG , et al. IMPACT-DCM: a randomized, controlled, multi-center phase II trial utilizing expanded autologous bone marrow as sole therapy for dilated cardiomyopathy study update. Journal of Heart and Lung Transplantation2011;30:79. BungeRR , PatelAN , HammanBL , LattoufOM , SmediraNG , BartelRL , et al. Safety and efficacy of ixmyelocel-t, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Heart and Lung Transplantation2012;31:72-3. HenryTD , TraverseJH , HammonBL , EastCA , BrucknerB , RemmersAE , et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circulation Research2014;115(8):730-7. [DOI: 10.1161/CIRCRESAHA.115.304554]PatelAN , HammanBL , BrucknerB , LattoufOM , SmediraNG , EastC , et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM). Journal of Cardiac Failure2011;17:58. ">Henry 2014</a> studied mixed population. Data shown here correspond specifically to participants with non‐ischaemic dilated cardiomyopathy. </p> <p><sup>b</sup><a href="./references#CD013433-bbs2-0005" title="Sant'AnnaRT , FracassoJ , ValleFH , CastroI , NardiNB , Sant'AnnaJR , et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Revista Brasileira de Cirurgia Cardiovascular2014;29(3):437-47. ">Sant'Anna 2014 (INTRACELL)</a> assessed mortality at 6 months, but provides information on additional deaths observed up to 12 months only in the SCT group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of mortality rates</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013433-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Stem cell therapy (any type) compared to peripheral therapy with granulocyte colony‐stimulating factor for dilated cardiomyopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>SCT (any type) compared to G‐CSF for DCM</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> DCM (non‐ischaemic)<br/><b>Setting:</b> hospital for procedure, follow‐up ambulatory<br/><b>Intervention:</b> SCT (any type)<br/><b>Comparison:</b> G‐CSF (peripheral therapy with granulocyte colony‐stimulating factor) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with SCT</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up to 5 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195<br/>(3 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.46</b><br/>(0.16 to 1.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>128 per 1000</b> </p> <p>(45 to 365)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether SCT reduces all‐cause mortality in people with DCM.</p> <p>See <a href="./full#CD013433-tbl-0002">Table 1</a> for more details on mortality. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Procedural complications (safety)</b> </p> <p>Follow‐up 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60</p> <p>(1 study)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether SCT increases the risk of procedural complications in people with DCM. </p> <p><a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a> assessed the safety of the SCT infusion by measurement of creatine kinase and troponin T concentrations 12 hours after infusion. There were no cases of distal coronary artery occlusion, acute cardiac dysfunction, or significant creatine kinase or troponin T release. 1 participant experienced a localized coronary dissection during infusion. No complications or adverse events associated with G‐CSF therapy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Follow‐up 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22<br/>(1 study) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.39</p> <p>(SD 14.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 4.61 higher</b> (5.62 lower to 14.83 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCT may not improve health‐related quality of life in people with DCM.</p> <p>For the risk with control, we used the mean of the control group of the only included study. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Performance status – functional class (NYHA)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Performance status – exercise tolerance (6MWT) (m)</b> </p> <p>Follow‐up to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155<br/>(2 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138.9</p> <p>(SD 61.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 140.14 m higher</b> (119.51 higher to 160.77 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCT may improve performance status assessed by 6MWT in people with DCM.</p> <p>For the 2 studies included in this analysis, we obtained raw data from a figure by using a software. </p> <p>For the risk with control, we used the mean average of the control groups of the included studies. </p> <p>1 additional study assessed exercise time and found an improvement with SCT (P = 0.01) but a decrease in the control group after 1 year (<a href="./references#CD013433-bbs2-0001" title="ArnousS , MozidA , MathurA . The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial: study design. Regenerative Medicine2011;6(4):525-33. EUCTR2009-013112-12-GB. Randomised controlled trial to compare the effects of G-CSF(Granocyte™) and autologous bone marrow progenitor cells on quality of life and left ventricular function In patients with idiopathic dilated cardiomyopathy – REGENERATE-DCM. ddrare.nibiohn.go.jp/cgi-bin/disease_who_e.cgi?id=57 (accessed prior to 1 July 2021). HamshereS , ArnousS , ChoudhuryT , ChoudryF , MozidA , YeoC , et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal2015;36(44):3061-9. [DOI: dx.doi.org/10.1093/eurheartj/ehv390]NCT01302171. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGEN-DCM). clinicaltrials.gov/ct2/show/NCT01302171 (first received 24 February 2011). ">Hamshere 2015</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MACE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported MACE as defined in our protocol (<a href="./references#CD013433-bbs2-0105" title="Diaz-NavarroR , UrrútiaG , ClelandJG , PoloniD , VillagranF , BangdiwalaS , et al. Stem cell therapy for dilated cardiomyopathy. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD013433. [DOI: 10.1002/14651858.CD013433]">Diaz‐Navarro 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>6MWT:</b> 6‐minute walk test; <b>CI:</b> confidence interval; <b>DCM:</b> dilated cardiomyopathy; <b>G‐CSF:</b> granulocyte colony‐stimulating factor; <b>MD:</b> mean difference; <b>NYHA:</b> New York Heart Association; <b>RR:</b> risk ratio; <b>SCT:</b> stem cell therapy; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for risk of bias due to serious concerns about selective reporting with two studies. In <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a>, there were inconsistencies between the trial register (NCT00629018) and the final publication regarding the total number of participants (110 vs 55), the time point for the outcomes (5 years vs 1 year) and some of the outcomes that were planned and finally reported, and there is a high suspicion that participants reported in <a href="./references#CD013433-bbs2-0007" title="VrtovecB , PoglajenG , SeverM , LezaicL , DomanovicD , CernelcP , et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Journal of Cardiac Failure2011;17(4):272-81. [DOI: dx.doi.org/10.1016/j.cardfail.2010.11.007]">Vrtovec 2011</a> were also included in the <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a> analysis. For <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a>, the trial was registered as a phase II study to compare between intracoronary versus intramyocardial injection of SCT (NCT01350310), nevertheless the publication described a comparison between SCT and no cell therapy. We made several attempts to contact the authors with no reply.<br/><sup>b</sup>Downgraded one level for indirectness due to concerns about the population. <a href="./references#CD013433-bbs2-0008" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+ stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-year follow up. Circulation Research2012;112:165-73. [DOI: 10.1161/circresaha.112.276519]VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Effects of intracoronary CD34+stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research2013;112(1):165-73. VrtovecB , SeverM , DomanovicD , LezaicL , PoglajenG , CernelcP , et al. Long-term effects of stem cell transplantation in heart failure. Zdravniski Vestnik2012;81(Suppl II):373-83. ">Vrtovec 2013a (NOGA‐DCM)</a> has a ClinicalTrials.gov record (NCT01350310), which had an actual primary completion date of August 2014, but the study was published in 2013 after 5 years' follow‐up. We made many attempts to contact the author with no reply.<br/><sup>c</sup>Downgraded two levels for imprecision due to optimal information size not being met. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Stem cell therapy (any type) compared to peripheral therapy with granulocyte colony‐stimulating factor for dilated cardiomyopathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013433-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">The Cochrane tool for assessing risk of bias</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Domain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Random sequence generation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0008"> <li> <p>Low risk: if sequence generation was achieved using computer random number generator or a random numbers table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were also considered adequate if performed by an independent adjudicator. </p> </li> <li> <p>Unclear risk: if the method of randomization was not specified, but the trial was still presented as being randomized. </p> </li> <li> <p>High risk: if the allocation sequence was not randomized or only quasi‐randomized; we excluded these trials. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0009"> <li> <p>Low risk: if the allocation of participants was performed by a central independent unit, on‐site locked computer, identical‐looking numbered sealed envelopes, syringes prepared by an independent investigator. </p> </li> <li> <p>Unclear risk: if the trial was classified as randomized but the allocation concealment process was not described. </p> </li> <li> <p>High risk: if the allocation sequence was familiar to the investigators who assigned participants. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Blinding of participants and personnel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0010"> <li> <p>Low risk: if the participants and the personnel were blinded to intervention allocation and this was described </p> </li> <li> <p>Unclear risk: if the procedure of blinding was insufficiently described or not described at all. </p> </li> <li> <p>High risk: if blinding of participants and personnel was not performed.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Blinding of outcome assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0011"> <li> <p>Low risk: if it was mentioned that outcome assessors were blinded and this was described.</p> </li> <li> <p>Unclear risk: if it was not mentioned if the outcome assessors in the trial were blinded, or the extent of blinding was insufficiently described. </p> </li> <li> <p>High risk: if no blinding or incomplete blinding of outcome assessors was performed.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incomplete outcome data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0012"> <li> <p>Low risk: if missing data were unlikely to make treatment effects depart from plausible values. This could either be: there were no dropouts or withdrawals for all outcomes, or the numbers and reasons for the withdrawals and dropouts for all outcomes were clearly stated and could be described as being similar in both groups. Generally, the trial was judged at low risk of bias due to incomplete outcome data if dropouts were less than 5%. However, the 5% cut‐off is not definitive. </p> </li> <li> <p>Unclear risk: if there was insufficient information to assess whether missing data were likely to have induced bias on the results. </p> </li> <li> <p>High risk: if the results were likely to be biased due to missing data either because the pattern of dropouts could be described as being different in the 2 intervention groups or the trial used improper methods in dealing with the missing data (e.g. last observation carried forward). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selective outcome reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0013"> <li> <p>Low risk: if a protocol was published before or at the time the trial was begun and the outcomes specified in the protocol were reported on. If there was no protocol or the protocol was published after the trial had begun, reporting of all‐cause mortality and periprocedural complications (the 2 primary outcomes) will grant the trial a grade of low risk. </p> </li> <li> <p>Unclear risk: if no protocol was published and the 2 primary outcomes were not reported on. </p> </li> <li> <p>High risk: if the outcomes in the protocol were not reported on.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other risks of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013433-list-0014"> <li> <p>Low risk: if the trial appeared free of other components (e.g. academic bias or for‐profit bias) that could have put it at risk of bias. </p> </li> <li> <p>Unclear risk: if the trial may or may not have been free of other components that could have put it at risk of bias. </p> </li> <li> <p>High risk: if there were other factors in the trial that could have put it at risk of bias (e.g. authors had conducted trials on the same topic, for‐profit bias, etc.). </p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>Table adapted from Table 8.5.d: Criteria for judging risk of bias in the risk of bias assessment tool, in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013433-bbs2-0069" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">The Cochrane tool for assessing risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013433-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of comparison 3</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Details on the specific comparison</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0002" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. MushtaqM , DiFedeDL , GolpanianS , KhanA , GomesSA , MendizabalA , et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research2014;7(9):769-80. RamireddyA , BrodtCR , MendizabalAM , DiFedeDL , HealyC , GoyalV , et al. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine2017;6:1366-72. [DOI: 10.1002/sctm.16-0328]">Hare 2017 (POSEIDON‐DCM)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Autologous vs allogeneic mesenchymal stem cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0009" title="VrtovecB , PoglajenG , LezaicL , SeverM , DomanovicD , CernelcP , et al. Comparison of clinical effects of transendocardial vs. intracoronary stem cell transplantation in dilated cardiomyopathy. Circulation2012;126:21. VrtovecB , PoglajenG , LezaicL , SeverM , SocanA , DomanovicD , et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation2013;128(11):S42-9. ">Vrtovec 2013b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intracoronary vs transendocardial delivery of stem cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0010" title="FrljakS , JaklicM , ZemljicG , CerarA , PoglajenG , VrtovecB . CD34(+) cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Translational Medicine2018;7:168-72. [DOI: 10.1002/sctm.17-0197]VrtovecB , PoglajenG , SeverM , ZemljicG , FrljakS , CerarA , et al. Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation Research2018;123(3):389-96. ">Vrtovec 2018 (REMEDIUM)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Repetitive vs single dose of stem cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013433-bbs2-0013" title="XiaoW , GuoS , GaoC , DaiG , GaoY , LiM , et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. International Heart Journal2017;58(2):238-44. [DOI: dx.doi.org/10.1536/ihj.16-328]">Xiao 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mononuclear vs mesenchymal bone marrow stem cells</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of comparison 3</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/full#CD013433-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013433-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.54, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.01, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Performance status – 6‐minute walk test (m) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>70.12 [‐5.28, 145.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Change in left ventricular ejection fraction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.41 [‐2.29, 13.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Change in left ventricular end‐systolic volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐30.97 [‐54.18, ‐7.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Change in left ventricular end‐diastolic volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐23.40 [‐49.74, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Stem cell therapy (SCT; any type) versus control (no intervention or sham intervention)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013433-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.16, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.61 [‐5.62, 14.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Performance status – 6‐minute walk test (m) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>140.14 [119.51, 160.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Change in left ventricular ejection volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.61 [5.61, 7.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Change in left ventricular end‐systolic volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐71.30 [‐150.96, 8.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Change in left ventricular end‐diastolic volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐81.10 [‐175.54, 13.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Change in plasma natriuretic peptide levels (BNP and NT‐proBNP) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1632.09 [‐2180.18, ‐1083.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Stem cell therapy (SCT; any type) versus peripheral therapy with granulocyte colony‐stimulating factor (G‐CSF)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013433.pub2/references#CD013433-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013433.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013433-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013433-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013433-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013433-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD013433-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013433-note-0013">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013433-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013433-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013433\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013433\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013433\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013433\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013433\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013433.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013433.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013433.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013433.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013433.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729503699"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013433.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729503703"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013433.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ede7cc805bd65',t:'MTc0MDcyOTUwNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 